EP1551418A1 - Substituted ketophosphonate compounds having bone anabolic activity - Google Patents
Substituted ketophosphonate compounds having bone anabolic activityInfo
- Publication number
- EP1551418A1 EP1551418A1 EP03752401A EP03752401A EP1551418A1 EP 1551418 A1 EP1551418 A1 EP 1551418A1 EP 03752401 A EP03752401 A EP 03752401A EP 03752401 A EP03752401 A EP 03752401A EP 1551418 A1 EP1551418 A1 EP 1551418A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dimethyl
- tert
- oxo
- butyl
- phosphonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims description 130
- 210000000988 bone and bone Anatomy 0.000 title claims description 55
- 230000001195 anabolic effect Effects 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 43
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 208000020084 Bone disease Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 88
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 86
- -1 phosphonate compound Chemical class 0.000 claims description 67
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 47
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 38
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 33
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 23
- 230000007170 pathology Effects 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000000148 hypercalcaemia Effects 0.000 claims description 14
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 14
- 230000011164 ossification Effects 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 206010027476 Metastases Diseases 0.000 claims description 12
- 230000009401 metastasis Effects 0.000 claims description 12
- 230000002308 calcification Effects 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 208000001132 Osteoporosis Diseases 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 238000002316 cosmetic surgery Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 230000036210 malignancy Effects 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000010392 Bone Fractures Diseases 0.000 claims description 6
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 6
- 208000027868 Paget disease Diseases 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 208000027202 mammary Paget disease Diseases 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- JDHYKZNWTVHWOP-UHFFFAOYSA-N 1-(3,5-ditert-butylphenyl)-2-diethoxyphosphorylpropan-1-one Chemical compound CCOP(=O)(OCC)C(C)C(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 JDHYKZNWTVHWOP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000004872 soft tissue Anatomy 0.000 claims description 5
- XYJGGZHIQCKPFV-UHFFFAOYSA-N 1-(3,5-ditert-butylphenyl)-2-dimethoxyphosphorylpropan-1-one Chemical compound COP(=O)(OC)C(C)C(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 XYJGGZHIQCKPFV-UHFFFAOYSA-N 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 208000003076 Osteolysis Diseases 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 230000000010 osteolytic effect Effects 0.000 claims description 4
- 208000028169 periodontal disease Diseases 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 230000001173 tumoral effect Effects 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 235000005282 vitamin D3 Nutrition 0.000 claims description 4
- 239000011647 vitamin D3 Substances 0.000 claims description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 229940021056 vitamin d3 Drugs 0.000 claims description 4
- RBGQWYRRQQTIGU-UHFFFAOYSA-N 1-(3,5-ditert-butyl-2-methoxyphenyl)-2-diethoxyphosphorylpropan-1-one Chemical compound CCOP(=O)(OCC)C(C)C(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1OC RBGQWYRRQQTIGU-UHFFFAOYSA-N 0.000 claims description 3
- QKKXROQJDMQEKM-UHFFFAOYSA-N 1-(3,5-ditert-butyl-2-methoxyphenyl)-2-dimethoxyphosphoryl-2-fluoropropan-1-one Chemical compound COC1=C(C(=O)C(C)(F)P(=O)(OC)OC)C=C(C(C)(C)C)C=C1C(C)(C)C QKKXROQJDMQEKM-UHFFFAOYSA-N 0.000 claims description 3
- YOUHQFLMFINIPL-UHFFFAOYSA-N 1-(3,5-ditert-butylphenyl)-2-dimethoxyphosphoryl-2-fluoropropan-1-one Chemical compound COP(=O)(OC)C(C)(F)C(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 YOUHQFLMFINIPL-UHFFFAOYSA-N 0.000 claims description 3
- GSGPSOTZXDCFCU-UHFFFAOYSA-N 1-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-diethoxyphosphorylpent-1-en-3-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2C=CC(=O)C(C)P(=O)(OCC)OCC GSGPSOTZXDCFCU-UHFFFAOYSA-N 0.000 claims description 3
- AMBYSZOMGHIEGP-UHFFFAOYSA-N 1-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-dimethoxyphosphorylpent-1-en-3-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2C=CC(=O)C(C)P(=O)(OC)OC AMBYSZOMGHIEGP-UHFFFAOYSA-N 0.000 claims description 3
- PNWATXQXZJBQDX-UHFFFAOYSA-N 1-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-diethoxyphosphorylpent-1-en-3-one Chemical compound C1CCCC2=C1C(OC)=C(C(C)(C)C)C=C2C=CC(=O)C(C)P(=O)(OCC)OCC PNWATXQXZJBQDX-UHFFFAOYSA-N 0.000 claims description 3
- FQWHMOOLNCSSNC-UHFFFAOYSA-N 1-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-dimethoxyphosphorylpent-1-en-3-one Chemical compound C1CCCC2=C(C=CC(=O)C(C)P(=O)(OC)OC)C=C(C(C)(C)C)C(OC)=C21 FQWHMOOLNCSSNC-UHFFFAOYSA-N 0.000 claims description 3
- VIKMLJNWAFJZOL-UHFFFAOYSA-N 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-1-dimethoxyphosphorylbut-3-en-2-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2C=CC(=O)CP(=O)(OC)OC VIKMLJNWAFJZOL-UHFFFAOYSA-N 0.000 claims description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 3
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 3
- 229940062527 alendronate Drugs 0.000 claims description 3
- 229960005370 atorvastatin Drugs 0.000 claims description 3
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 3
- 229960005110 cerivastatin Drugs 0.000 claims description 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 3
- 229960002286 clodronic acid Drugs 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940009626 etidronate Drugs 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 229940015872 ibandronate Drugs 0.000 claims description 3
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 3
- 229950006971 incadronic acid Drugs 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 3
- 229940046231 pamidronate Drugs 0.000 claims description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- 229940089617 risedronate Drugs 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 229940019375 tiludronate Drugs 0.000 claims description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 3
- 229960004276 zoledronic acid Drugs 0.000 claims description 3
- QPODFEVVGYTYIP-UHFFFAOYSA-N 1-(3,5-ditert-butyl-2-hydroxyphenyl)-4-dimethoxyphosphoryl-4-methylpentan-3-one Chemical compound COP(=O)(OC)C(C)(C)C(=O)CCC1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1O QPODFEVVGYTYIP-UHFFFAOYSA-N 0.000 claims description 2
- KXCHODVXPWWQBS-UHFFFAOYSA-N 1-(3,5-ditert-butyl-2-methoxyphenyl)-2-diethoxyphosphoryl-2-fluoropropan-1-one Chemical compound CCOP(=O)(OCC)C(C)(F)C(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1OC KXCHODVXPWWQBS-UHFFFAOYSA-N 0.000 claims description 2
- GWOPNHSEZRVNDM-UHFFFAOYSA-N 1-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-diethoxyphosphoryl-4-fluoropent-1-en-3-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2C=CC(=O)C(C)(F)P(=O)(OCC)OCC GWOPNHSEZRVNDM-UHFFFAOYSA-N 0.000 claims description 2
- BSHSFMBMOYXOGQ-UHFFFAOYSA-N 1-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-dimethoxyphosphoryl-4-fluoropent-1-en-3-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2C=CC(=O)C(C)(F)P(=O)(OC)OC BSHSFMBMOYXOGQ-UHFFFAOYSA-N 0.000 claims description 2
- PKGIMYYMXPYXDX-UHFFFAOYSA-N 1-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-2-diethoxyphosphoryl-2-fluoropropan-1-one Chemical compound C1CCCC2=C1C(OC)=C(C(C)(C)C)C=C2C(=O)C(C)(F)P(=O)(OCC)OCC PKGIMYYMXPYXDX-UHFFFAOYSA-N 0.000 claims description 2
- UWOINOVUUUTMQE-UHFFFAOYSA-N 1-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-dimethoxyphosphoryl-4-fluoropent-1-en-3-one Chemical compound C1CCCC2=C(C=CC(=O)C(C)(F)P(=O)(OC)OC)C=C(C(C)(C)C)C(OC)=C21 UWOINOVUUUTMQE-UHFFFAOYSA-N 0.000 claims description 2
- SZKNTNRDDYJSQU-UHFFFAOYSA-N 1-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-dimethoxyphosphoryl-4-methylhex-1-en-3-one Chemical compound C1CCCC2=C1C(OC)=C(C(C)(C)C)C=C2C=CC(=O)C(C)(CC)P(=O)(OC)OC SZKNTNRDDYJSQU-UHFFFAOYSA-N 0.000 claims description 2
- GSSCVESOAWIAQX-UHFFFAOYSA-N 1-(5-tert-butyl-2-hydroxy-3-methoxyphenyl)-4-dimethoxyphosphoryl-4-methylpent-1-en-3-one Chemical compound COC1=CC(C(C)(C)C)=CC(C=CC(=O)C(C)(C)P(=O)(OC)OC)=C1O GSSCVESOAWIAQX-UHFFFAOYSA-N 0.000 claims description 2
- JAQRFZPCQVOODC-UHFFFAOYSA-N 1-(5-tert-butyl-2-hydroxy-3-methoxyphenyl)-4-dimethoxyphosphoryl-4-methylpentan-3-one Chemical compound COC1=CC(C(C)(C)C)=CC(CCC(=O)C(C)(C)P(=O)(OC)OC)=C1O JAQRFZPCQVOODC-UHFFFAOYSA-N 0.000 claims description 2
- IBWSXMXDYKHRJB-UHFFFAOYSA-N 2-diethoxyphosphoryl-2-methyl-1-(3,4,5-trimethoxyphenyl)propan-1-one Chemical compound CCOP(=O)(OCC)C(C)(C)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 IBWSXMXDYKHRJB-UHFFFAOYSA-N 0.000 claims description 2
- MYOSARARYKKEEN-UHFFFAOYSA-N 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-1-diethoxyphosphorylbut-3-en-2-one Chemical compound CCOP(=O)(CC(=O)C=Cc1cc(c(O)c2CCCCc12)C(C)(C)C)OCC MYOSARARYKKEEN-UHFFFAOYSA-N 0.000 claims description 2
- YDDYJOWCHJGRMF-UHFFFAOYSA-N 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-1-dimethoxyphosphorylbut-3-en-2-one Chemical compound C1CCCC2=C(C=CC(=O)CP(=O)(OC)OC)C=C(C(C)(C)C)C(OC)=C21 YDDYJOWCHJGRMF-UHFFFAOYSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- YIDZQOHOFHMEKZ-UHFFFAOYSA-N 1-(3,5-ditert-butylphenyl)-2-dimethoxyphosphoryl-2,2-difluoroethanone Chemical compound COP(=O)(OC)C(F)(F)C(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 YIDZQOHOFHMEKZ-UHFFFAOYSA-N 0.000 claims 1
- IBVHBOQCDYFZDD-UHFFFAOYSA-N 1-(3-benzyl-4-hydroxynaphthalen-1-yl)-4-dimethoxyphosphoryl-4-methylpent-1-en-3-one Chemical compound OC=1C2=CC=CC=C2C(C=CC(=O)C(C)(C)P(=O)(OC)OC)=CC=1CC1=CC=CC=C1 IBVHBOQCDYFZDD-UHFFFAOYSA-N 0.000 claims 1
- LAKXWEKEYIMOAR-UHFFFAOYSA-N 1-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-dimethoxyphosphoryl-4-methylhex-1-en-3-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2C=CC(=O)C(C)(CC)P(=O)(OC)OC LAKXWEKEYIMOAR-UHFFFAOYSA-N 0.000 claims 1
- KNOIJFHILIFISJ-UHFFFAOYSA-N 4-dimethoxyphosphoryl-1-(4-hydroxy-3-methoxy-5-methylphenyl)-4-methylpent-1-en-3-one Chemical compound COC1=CC(C=CC(=O)C(C)(C)P(=O)(OC)OC)=CC(C)=C1O KNOIJFHILIFISJ-UHFFFAOYSA-N 0.000 claims 1
- JSDKWAAQXFNQQP-UHFFFAOYSA-N 4-dimethoxyphosphoryl-1-(4-hydroxy-3-methoxy-5-propylphenyl)-4-methylpent-1-en-3-one Chemical compound CCCC1=CC(C=CC(=O)C(C)(C)P(=O)(OC)OC)=CC(OC)=C1O JSDKWAAQXFNQQP-UHFFFAOYSA-N 0.000 claims 1
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 64
- 230000002265 prevention Effects 0.000 abstract description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 159
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 114
- 239000000243 solution Substances 0.000 description 96
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 86
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
- 229910052681 coesite Inorganic materials 0.000 description 43
- 229910052906 cristobalite Inorganic materials 0.000 description 43
- 239000000377 silicon dioxide Substances 0.000 description 43
- 229910052682 stishovite Inorganic materials 0.000 description 43
- 229910052905 tridymite Inorganic materials 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
- 229910001868 water Inorganic materials 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 238000004440 column chromatography Methods 0.000 description 31
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 31
- 235000019341 magnesium sulphate Nutrition 0.000 description 29
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 235000012239 silicon dioxide Nutrition 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- 239000012071 phase Substances 0.000 description 23
- 239000012267 brine Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000001035 drying Methods 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 16
- 239000008346 aqueous phase Substances 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- 230000007062 hydrolysis Effects 0.000 description 14
- 238000006460 hydrolysis reaction Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000010626 work up procedure Methods 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 10
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 229910052744 lithium Inorganic materials 0.000 description 10
- 239000002480 mineral oil Substances 0.000 description 10
- 235000010446 mineral oil Nutrition 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 6
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 6
- 208000004434 Calcinosis Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- AATNZNJRDOVKDD-UHFFFAOYSA-N 1-[ethoxy(ethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(CC)OCC AATNZNJRDOVKDD-UHFFFAOYSA-N 0.000 description 5
- SWCHIZAAFNBZED-UHFFFAOYSA-N 3,5-ditert-butyl-2-methoxybenzaldehyde Chemical compound COC1=C(C=O)C=C(C(C)(C)C)C=C1C(C)(C)C SWCHIZAAFNBZED-UHFFFAOYSA-N 0.000 description 5
- KYVAHAOTSOIGRY-UHFFFAOYSA-N 3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalene-1-carbaldehyde Chemical compound C1CCCC2=C(C=O)C=C(C(C)(C)C)C(OC)=C21 KYVAHAOTSOIGRY-UHFFFAOYSA-N 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- QGVSOOVQISEALB-UHFFFAOYSA-N ethyl 3-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)prop-2-enoate Chemical compound C1CCCC2=C1C(OC)=C(C(C)(C)C)C=C2C=CC(=O)OCC QGVSOOVQISEALB-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- NYYLZXREFNYPKB-UHFFFAOYSA-N 1-[ethoxy(methyl)phosphoryl]oxyethane Chemical compound CCOP(C)(=O)OCC NYYLZXREFNYPKB-UHFFFAOYSA-N 0.000 description 4
- RRIQVLZDOZPJTH-UHFFFAOYSA-N 3,5-di-tert-butyl-2-hydroxybenzaldehyde Chemical compound CC(C)(C)C1=CC(C=O)=C(O)C(C(C)(C)C)=C1 RRIQVLZDOZPJTH-UHFFFAOYSA-N 0.000 description 4
- HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002617 bone density conservation agent Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000002997 osteoclast Anatomy 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- NWPRXAIYBULIEI-UHFFFAOYSA-N 2-(methoxycarbonylamino)-3,3-dimethylbutanoic acid Chemical compound COC(=O)NC(C(O)=O)C(C)(C)C NWPRXAIYBULIEI-UHFFFAOYSA-N 0.000 description 3
- BRUITYMDHWNCIG-UHFFFAOYSA-N 3,5-ditert-butylbenzaldehyde Chemical compound CC(C)(C)C1=CC(C=O)=CC(C(C)(C)C)=C1 BRUITYMDHWNCIG-UHFFFAOYSA-N 0.000 description 3
- RVAKIXIMFKPKJU-UHFFFAOYSA-N 3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalene-1-carbaldehyde Chemical compound C1CCCC2=C(O)C(C(C)(C)C)=CC(C=O)=C21 RVAKIXIMFKPKJU-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 3
- DVKDEXRJXRRZNI-UHFFFAOYSA-N ethyl 3-(3,5-ditert-butylphenyl)prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 DVKDEXRJXRRZNI-UHFFFAOYSA-N 0.000 description 3
- FUWSSPCXTYWJQY-UHFFFAOYSA-N ethyl 3-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)prop-2-enoate Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2C=CC(=O)OCC FUWSSPCXTYWJQY-UHFFFAOYSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- WFSKAYCTJPEINJ-UHFFFAOYSA-N 1-(3,5-ditert-butyl-2-hydroxyphenyl)-4-diethoxyphosphoryl-4-fluoropent-1-en-3-one Chemical compound CCOP(=O)(OCC)C(C)(F)C(=O)C=CC1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1O WFSKAYCTJPEINJ-UHFFFAOYSA-N 0.000 description 2
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 2
- LGONQAKEHPJYDG-UHFFFAOYSA-N 1-[3,5-ditert-butyl-2-(2-methoxyethoxymethoxy)phenyl]-4-diethoxyphosphorylpent-1-en-3-one Chemical compound CCOP(=O)(OCC)C(C)C(=O)C=CC1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1OCOCCOC LGONQAKEHPJYDG-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- WURPICKQYPNSMH-UHFFFAOYSA-N 3,5-ditert-butyl-2-(2-methoxyethoxymethoxy)benzaldehyde Chemical compound COCCOCOC1=C(C=O)C=C(C(C)(C)C)C=C1C(C)(C)C WURPICKQYPNSMH-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- LJDQEZDCGZFJHQ-UHFFFAOYSA-N C=CC(C(OP(O)=O)=C1CCCC1)=O Chemical compound C=CC(C(OP(O)=O)=C1CCCC1)=O LJDQEZDCGZFJHQ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- UEOFNBCUGJADBM-UHFFFAOYSA-N Ethyl 3,4,5-trimethoxybenzoate Chemical compound CCOC(=O)C1=CC(OC)=C(OC)C(OC)=C1 UEOFNBCUGJADBM-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229910003074 TiCl4 Inorganic materials 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 230000000123 anti-resoprtive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- WPIWCBYPPOTSPV-UHFFFAOYSA-N ethyl 3,5-ditert-butylbenzoate Chemical compound CCOC(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 WPIWCBYPPOTSPV-UHFFFAOYSA-N 0.000 description 2
- KDBUSUXBKXUZBY-UHFFFAOYSA-N ethyl 3-(3,5-ditert-butyl-2-methoxyphenyl)prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1OC KDBUSUXBKXUZBY-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- JRRYKTYVRFRFMB-UHFFFAOYSA-N methyl 3,5-ditert-butyl-2-methoxybenzoate Chemical compound COC(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1OC JRRYKTYVRFRFMB-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- DKUWFRZJHBRVHP-UHFFFAOYSA-N 1-(3,5-ditert-butylphenyl)-2-dimethoxyphosphoryl-2-methylpropan-1-one Chemical compound COP(=O)(OC)C(C)(C)C(=O)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 DKUWFRZJHBRVHP-UHFFFAOYSA-N 0.000 description 1
- LXJXHJOWQBCGNX-UHFFFAOYSA-N 1-(3-cyclopentyloxy-4-methoxyphenyl)-4-dimethoxyphosphoryl-4-methylpent-1-en-3-one Chemical compound COC1=CC=C(C=CC(=O)C(C)(C)P(=O)(OC)OC)C=C1OC1CCCC1 LXJXHJOWQBCGNX-UHFFFAOYSA-N 0.000 description 1
- ZICSOPABLMGNEM-UHFFFAOYSA-N 1-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-dimethoxyphosphoryl-4-methylpentan-3-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2CCC(=O)C(C)(C)P(=O)(OC)OC ZICSOPABLMGNEM-UHFFFAOYSA-N 0.000 description 1
- MSBNCOPNNPPKAR-UHFFFAOYSA-N 1-(3-tert-butyl-4-hydroxynaphthalen-1-yl)-4-dimethoxyphosphoryl-4-methylpent-1-en-3-one Chemical compound C1=CC=C2C(C=CC(=O)C(C)(C)P(=O)(OC)OC)=CC(C(C)(C)C)=C(O)C2=C1 MSBNCOPNNPPKAR-UHFFFAOYSA-N 0.000 description 1
- RAAFZUWWGWKGMK-UHFFFAOYSA-N 1-[3-tert-butyl-4-(2-methoxyethoxymethoxy)-5,6,7,8-tetrahydronaphthalen-1-yl]-4-dimethoxyphosphorylpent-1-en-3-one Chemical compound C1CCCC2=C(C=CC(=O)C(C)P(=O)(OC)OC)C=C(C(C)(C)C)C(OCOCCOC)=C21 RAAFZUWWGWKGMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 1
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
- FHFQSSIJNGNLAC-UHFFFAOYSA-N 3,5-dicyclopentyl-4-hydroxybenzaldehyde Chemical compound OC1=C(C2CCCC2)C=C(C=O)C=C1C1CCCC1 FHFQSSIJNGNLAC-UHFFFAOYSA-N 0.000 description 1
- FVCJFTILMZRUER-UHFFFAOYSA-N 3,5-diethoxy-4-hydroxybenzaldehyde Chemical compound CCOC1=CC(C=O)=CC(OCC)=C1O FVCJFTILMZRUER-UHFFFAOYSA-N 0.000 description 1
- MPGQQFNWZHRKIS-UHFFFAOYSA-N 3,5-ditert-butyl-2-methoxybenzoic acid Chemical compound COC1=C(C(O)=O)C=C(C(C)(C)C)C=C1C(C)(C)C MPGQQFNWZHRKIS-UHFFFAOYSA-N 0.000 description 1
- QJSYSEKBLJXXTM-UHFFFAOYSA-N 3-benzyl-4-hydroxynaphthalene-1-carbaldehyde Chemical compound C1=C(C=O)C2=CC=CC=C2C(O)=C1CC1=CC=CC=C1 QJSYSEKBLJXXTM-UHFFFAOYSA-N 0.000 description 1
- FZFWPURYSWKIRT-UHFFFAOYSA-N 3-cyclopentyloxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC1CCCC1 FZFWPURYSWKIRT-UHFFFAOYSA-N 0.000 description 1
- NVLTWXMZECWWPC-UHFFFAOYSA-N 3-hydroxy-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(O)=C1OC NVLTWXMZECWWPC-UHFFFAOYSA-N 0.000 description 1
- BMDAIIMNKBGMKW-UHFFFAOYSA-N 3-tert-butyl-4-(2-methoxyethoxymethoxy)-5,6,7,8-tetrahydronaphthalene-1-carbaldehyde Chemical compound C1CCCC2=C(C=O)C=C(C(C)(C)C)C(OCOCCOC)=C21 BMDAIIMNKBGMKW-UHFFFAOYSA-N 0.000 description 1
- AXAFNTSHWBEXFQ-UHFFFAOYSA-N 3-tert-butyl-4-hydroxy-5,5-dimethyl-7,8-dihydro-6h-naphthalene-1-carbaldehyde Chemical compound C1CCC(C)(C)C2=C(O)C(C(C)(C)C)=CC(C=O)=C21 AXAFNTSHWBEXFQ-UHFFFAOYSA-N 0.000 description 1
- WRWHSTFUHZNZFM-UHFFFAOYSA-N 3-tert-butyl-4-hydroxynaphthalene-1-carbaldehyde Chemical compound C1=CC=CC2=C(O)C(C(C)(C)C)=CC(C=O)=C21 WRWHSTFUHZNZFM-UHFFFAOYSA-N 0.000 description 1
- SMVKCCGARJXFAG-UHFFFAOYSA-N 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-1-dimethoxyphosphorylbutan-2-one Chemical compound C1CCCC2=C1C(O)=C(C(C)(C)C)C=C2CCC(=O)CP(=O)(OC)OC SMVKCCGARJXFAG-UHFFFAOYSA-N 0.000 description 1
- TZHLBMDUUXOTTM-UHFFFAOYSA-N 4-dimethoxyphosphoryl-1-(3-hydroxy-4,5-dimethoxyphenyl)-4-methylpent-1-en-3-one Chemical compound COC1=CC(C=CC(=O)C(C)(C)P(=O)(OC)OC)=CC(O)=C1OC TZHLBMDUUXOTTM-UHFFFAOYSA-N 0.000 description 1
- IDOZBVDISKHFPQ-UHFFFAOYSA-N 4-dimethoxyphosphoryl-4-methyl-1-(3,4,5-trimethoxyphenyl)pent-1-en-3-one Chemical compound COC1=CC(C=CC(=O)C(C)(C)P(=O)(OC)OC)=CC(OC)=C1OC IDOZBVDISKHFPQ-UHFFFAOYSA-N 0.000 description 1
- MGJSDNCLGHCTIL-UHFFFAOYSA-N 4-hydroxy-3-methoxy-5-methylbenzaldehyde Chemical compound COC1=CC(C=O)=CC(C)=C1O MGJSDNCLGHCTIL-UHFFFAOYSA-N 0.000 description 1
- YSJUSJJVBIDDHP-UHFFFAOYSA-N 4-hydroxy-3-methoxy-5-propylbenzaldehyde Chemical compound CCCC1=CC(C=O)=CC(OC)=C1O YSJUSJJVBIDDHP-UHFFFAOYSA-N 0.000 description 1
- UXQYPROJNFZQDU-UHFFFAOYSA-N 5-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-ethyl-2-fluorohept-4-en-3-one Chemical compound C(C)C(=C(C(C(C)F)=O)CC)C1=CC(=C(C=2CCCCC1=2)OC)C(C)(C)C UXQYPROJNFZQDU-UHFFFAOYSA-N 0.000 description 1
- LDMUWZJNLSNAJX-UHFFFAOYSA-N 5-tert-butyl-2-hydroxy-3-methoxybenzaldehyde Chemical compound COC1=CC(C(C)(C)C)=CC(C=O)=C1O LDMUWZJNLSNAJX-UHFFFAOYSA-N 0.000 description 1
- 208000028906 Abnormal bone structure Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000011795 OF1 mouse Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- TWCNQHVRGFBHTE-UHFFFAOYSA-N ethyl 3-[3,5-ditert-butyl-2-(2-methoxyethoxymethoxy)phenyl]prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1OCOCCOC TWCNQHVRGFBHTE-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4015—Esters of acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4018—Esters of cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
- C07F9/4059—Compounds containing the structure (RY)2P(=X)-(CH2)n-C(=O)-(CH2)m-Ar, (X, Y = O, S, Se; n>=1, m>=0)
Definitions
- the present invention relates to the use of novel substituted ketophosphonate compounds in the treatment and/or prevention of bone diseases requiring, such as osteoporosis, through enhanced bone anabolic activity.
- Bone remodelling and repair is a tightly regulated process that continues throughout a person's lifetime. Bone formation requires the activity of the osteoblasts, the bone forming cells, whereas bone resorption results from the action of the osteoclasts. Consequently, two therapeutic approaches toward bone mass manipulation are currently investigated, namely, prevention of bone resorption and stimulation of bone formation (bone anabolism).
- a preferred approach for the prevention and/or treatment of bone diseases is to increase bone formation by stimulation of osteoblasts.
- therapeutic agents which stimulate bone formation or inhibit bone turnover are hormones or derivatives of hormones (estrogens, anabolic steroids, calcitonin, parathyroid hormone, vitamin D) with numerous side effects resulting from their hormonal activities.
- Sodium fluoride the old prophylatic for dental caries, is still the most widely used compound for the stimulation of bone formation. There is thus a need for new active compounds, preferably oral agents, that act by stimulating bone formation.
- the bisphosphonic acids (BP; also known as diphosphonic acids) and their salts are a class of compounds that are cytotoxic to osteoclasts and act to prevent bone resorption. These compounds have no effect on osteoblasts.
- Anti-resorptive bisphosphonic acids are currently used for the treatment of various bone diseases such as osteoporosis, hypercalcemia due to malignancies and inhibition of tumor cell metastasis in bone tissue. Despite their proven pharmacologic efficacy, the clinical utility of bisphosphonic acids is limited by their very low oral bioavailability and their gastrointestinal toxicity. It has also been reported that statins have bone anabolic activity and prevent fractures in patients.
- HMG-CoA reductase inhibitors induce BMP-2 synthesis and osteoblastic differentiation
- this class of inhibitors is characterized by a high degree of toxicity when systemically available.
- current inhibitors of HMG-CoA reductase were designed to target the liver and induce hypocholesterolemia, and are also known to trigger a positive feed-back resulting in the upregulation of the large majority of genes involved in isoprenoids and cholesterol synthesis.
- these compounds have significant drawbacks in the context of the treatment of bone diseases.
- substituted phosphonates of formula (I) have bone anabolic activity and are thereby useful in the treatment of bone diseases.
- One aspect of the invention are substituted phosphonate compounds of the formula (I): z ⁇
- X° is H, OH or a straight or branched d to C 6 alkoxy group
- X 1 , X 2 and X 3 are independently H, OH, a straight, branched or cyclic C ⁇ -C 6 alkyl or alkoxy group; or X , X or X , X together may form a C ⁇ - C g optionally substituted alkylidenoxy or alkylidenedioxy group; with the proviso that X is H when X is H and X and X are independently straight or branched C ⁇ - C ⁇ 5 alkyl groups; X 4 , X 5 , X 6 are independently H, a straight or branched Ci - C 6 alkyl group; q is zero or 1 ;
- X 7 is H, a straight or branched Ci - C 8 alkyl or alkoxy group, or an optionally substituted benzyl group;
- Y is O or S;
- Z 1 and Z2 are independently OR 1 or NR 2 R 3 , where R 1 , R 2 , and R 3 are independently H or a
- L is a saturated or unsaturated - C ⁇ alkylene chain in which one or more of the methylene groups can be replaced by a sulfur atom, an oxygen atom, a carbonyl group wherein optionally one or more methylene groups can be substituted by one or more halogen atoms (F, Cl or Br), -C ⁇ alkyl, an optionally substituted aryl or heteroaryl group.
- the present invention also encompasses pharmaceutically acceptable salts, solvates and hydrates of compounds of formula
- -B- is -C(R 6 )(R 7 )- where R 6 ,R 7 identical or different are H, Halogen (F, Cl, Br), C ⁇ -C 6 straight or branched alkyl, an optionally substituted aryl or heteroaryl, or R 6 and R 7 can form a ring of C 3 -O 7 carbon atoms.
- alkyl and "alkoxy" as used herein in relation to X°, X 1 , X 2 , X 3 , X 6 , R 1 , R 2 , R 3 , R 4 and R 5 means as indicated saturated straight, branched or cyclic substitutents, i.e., straight or branched -(C n H n+1 ) or -O(C n H 2n+1 ) or cyclic -(C n H n - ⁇ )- or -O-(C
- a ⁇ so includes halogenated alkyl and alkoxy groups and derivatives thereof, such as fluoro-substituted groups, fluorohydroxy substituted groups wherein the degree of halogenation ranges from a single halo substituent, e.g., -CH 2 F and -OCH 2 F, to perhalo-substituted alkyl and alkoxy groups, e
- X° is H, OH, OMe, X 3 is H, OH, Me, OMe, X 1 and X 2 are independently a straight or branched Ci - C 6 alkyl, a straight or branched Ci - C 6 alkoxy group; with the proviso that X° is H when X 3 is H, and X 1 and X 2 are independently a straight or branched Ci - C 6 alkyl groups;
- Y is O;
- Z 1 and Z 2 are the same and are OR 1 wherein R 1 is methyl, ethyl or isopropyl;
- Ar is:
- X° is H, OH, OMe
- X 4 is H, a straight, branched or cyclic to C 8 alkyl or alkoxy group, more preferably X 4 is a tert-butyl group
- X 5 and X 6 are indepdently H, a C 1 -C 4 alkyl group, more preferably X 5 and X 6 are H; q is zero or 1, more preferably q is 1;
- X° is H, OH, SH, OMe, SMe group
- X is H, a straight or branched C ⁇ - C 8 alkyl or alkoxy group, preferably a t-butyl group or an optionally substituted benzyl group;
- Y is O
- Z and Z 2 are the same and are OR 1 wherein R 1 is methyl, ethyl or isopropyl;
- novel substituted phosphonate compound of formula 1 is novel substituted phosphonate compound of formula 1.
- Embodiments also encompass pharmaceutical compositions of the substituted phosphonate compounds of formula (I) comprising a pharmaceutically acceptable carrier.
- Another aspect of the present invention is a method of treating or preventing a bone disease or pathology, comprising administering to a subject in need of such treatment an amount effective to stimulate bone formation of a substituted phosphonate compound of formula (I).
- the bone disease or pathology is osteoporosis, Paget's disease, bone fracture, hormone-induced bone pathologies, hyperparathyroidism, peridontal disease, post- plastic surgery, post-prosthetic joint surgery, post-dental implantation, hypercalcemia secondary to malignancies or hyperparathyroidism, a condition arising from hypercalcemia, including calcification of soft tissue (e.g., kidney, vessel walls and heart values), calcification of surgical implants and calcification of arteries (e.g., due to late stage atherosclerosis).
- soft tissue e.g., kidney, vessel walls and heart values
- calcification of surgical implants calcification of arteries (e.g., due to late stage atherosclerosis).
- the subject is characterized by a condition selected from the group consisting of osteoporosis, Paget's disease, bone fracture or deficiency, drug and hormone-induced bone pathologies (e.g., corticoids, retinoids and vitamin D3 induced bone pathologies), hype arathyroidism, periodontal disease or defect, post-plastic surgery, post-prosthetic joint surgery post-dental implantation, metastasis of cancer cells in bones, including osteolytic or osteoplastic bone metastasis, tumoral osteolysis, and hypercalcemia, wherein said hypercalcemia is secondary to malignancies.
- a condition selected from the group consisting of osteoporosis, Paget's disease, bone fracture or deficiency, drug and hormone-induced bone pathologies (e.g., corticoids, retinoids and vitamin D3 induced bone pathologies), hype arathyroidism, periodontal disease or defect, post-plastic surgery, post-prosthetic joint surgery post-dental implantation, metastasis of
- the method further comprises administration to the subject an effective amount of a bone resorption inhibitor, which may be alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, S-12911, raloxifene, simvastatin, atorvastatin, cerivastatin, vitamin D or calcitonin.
- a bone resorption inhibitor which may be alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, S-12911, raloxifene, simvastatin, atorvastatin, cerivastatin, vitamin D or calcitonin.
- statins mevalonate/isoprenoid/cholesterol
- BMP-2 bone morphogenetic protein-2
- the MIC pathway also provides isoprenoids, e.g., farnesylpyrophosphate and geranylgeranylpyrophosphate, compounds that serve as important lipid anchors for the post-translational modification of a variety of cell signalling proteins such as Rap, Ras and Rho.
- compositions for use in the present invention include those described by Berge et al. (1977). Such salts may be formed from inorganic and organic acids. Representative examples thereof include salts formed from alkali metals such as potassium and sodium. Since the compounds of the present invention are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I). Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.
- solvent of crystallisation may be present in the crystalline product.
- This invention includes within its scope such solvates.
- some of the compounds of this invention maybe crystallised or recrystallised from solvents containing water. In such cases water of hydration may be formed.
- This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
- different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products.
- This invention includes within its scope all polymorphic forms of the compounds of formula (I).
- the compounds of formula (I) can be administered by any of a variety of routes.
- they can be administered orally, or by delivery across another mucosal surface (for example across the nasal, buccal, bronchial or rectal mucosa), transdermally, or by injection (for example intradermal, intraperitoneal, intravenous or intramuscular injection).
- the compounds When the compounds are intended for oral administration, they can be formulated, for example, as tablets, capsules, ovules, granules, pills, lozenges, powders, solutions, emulsions, syrups, elixirs, suspensions, or any other pharmaceutical form suitable for oral administration.
- Oral dosage forms can, if desired, be coated with one or more release delaying coatings to allow the release of the active compound to be controlled or targeted at a particular part of the enteric tract. Tablets and other solid or liquid oral dosage forms can be prepared (e.g., in standard fashion) from the compounds of formula (I) and a pharmaceutically acceptable solubilizer, diluent or carrier.
- solubilizers, diluents or carriers include sugars such as lactose, starches, cellulose and its derivatives, powdered tracaganth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols such as glycerol, propyleneglycol and polyethyleneglycols, alginic acids and alginates, agar, pyrogen free water, isotonic saline, phosphate buffered solutions, and optionally other pharmaceutical excipients such as disintegrants, lubricants, wetting agents such as sodium lauryl sulfate, coloring agents, flavoring agents and preservatives, etc.
- sugars such as lactose, starches, cellulose and its derivatives, powdered tracaganth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols such
- Capsules can be of the hard or soft variety and can contain the active compound in solid, liquid or semisolid form. Typically such capsules are formed from gelatine or an equivalent substance and can be coated or uncoated. If it is desired to delay the release of the active compound until the capsule has passed through the stomach and into the intestine, the capsule can be provided with a pH sensitive coating adapted to dissolve at the pH found in the duodenum or ileum. Examples of such coatings include the Eudragits, the uses of which are well known. Formulations for injection will usually be made up of the appropriate solubilizers such as detergents which may also include compounds and excipients such as buffering agents to provide an isotonic solution having the correct physiological pH.
- solubilizers such as detergents which may also include compounds and excipients such as buffering agents to provide an isotonic solution having the correct physiological pH.
- the injectable solutions are typically pyrogen-free and can be provided in sealed vials or ampoules containing a unit dose of compound.
- parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatine capsule.
- Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
- a typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- composition is in unit dose form such as a tablet or capsule.
- a unit dosage form of the compounds of the invention typically will contain from 0.1% to 99% by weight of the active substance, more usually from 5% to 75% of the active substance.
- a unit dosage form can contain from 1 mg to 1 g of the compound, more usually from 10 mg to 500 mg, for example between 50 mg and 400 mg, and typically in doses of l00 mg to 200 mg.
- Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
- the compounds of the invention will be administered in amounts that are effective to provide the desired therapeutic effect.
- concentrations necessary to provide the desired therapeutic effect will vary according to among other things the precise nature of the disease, the size, weight and age of the patient and the severity of the disease.
- the doses administered will preferably be non-toxic to the patient, although in certain circumstances the severity of the disease under treatment may necessitate administering an amount of compound that causes some signs of toxicity.
- the compounds of the invention will be administered in amounts in the range 0.01 mg/kg tolOO mg/kg body weight, more preferably 0.1 g kg to 10 mg kg body weight and particularly 1 mg kg to 5 mg kg body weight.
- the pharmaceutically acceptable compounds of the invention will normally be administered to a subject in a daily dosage regimen. For an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
- a typical daily dosage of the compounds of the invention would be in the range of 70 mg to 700 mg.
- Such a dosage can be administered, for example from two to four times daily.
- the size of the doses administered and the frequency of administration will be at the discretion and judgement of the physician treating the patient.
- Bone resorption inhibitors are those agents known in the art to inhibit the absorption of bone and include, but are not limited to the following classes of compounds: bisphosphonic acids, such as alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, and S-12911; Selective Estrogen Receptor Modulators (SERMs), such as: raloxifene; HMG-CoA reductase inhibitors, such as simvastatin, atorvastatin and cerivastatin; steroid hormones, such as Vitamin D; and polypeptide hormones, such as calcitonin.
- SERMs Selective Estrogen Receptor Modulators
- Dosage ranges and regimens for bone resorption inhibitors are those which are known in the art.
- a bisphosphonic acid when employed, a daily dosage of 2.5 to 100 mg may be used.
- the components of a combination of the compounds of the present invention and bone resorption inhibitors can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
- the term "administering" is to be understood as embracing all such regimes of simultaneous or alternating treatment and the scope of combinations of the compounds of this invention and bone resorption inhibitors includes in principle, any combination useful for inhibiting bone loss and building new bone.
- Bone states which could benefit from increasing bone formation include, but are not limited to: osteoporosis; prevention and accelerated repair of bone fracture; prevention and treatment of metastasis of cancer cells in bone; prevention and treatment of osteolytic bone lesions; prevention and treatment of osteoblastic bone metastasis; prevention and treatment of increased bone remodeling, bone hypertrophy and abnormal bone structure (i.e., Paget's disease); prevention and treatment of bone loss associated with cancer therapies (e.g., bone loss associated with the treatment of gonadotropin-releasing hormone agonists for prostate cancer and bone loss associated with chemotherapy for breast cancer, wherein such chemotherapy includes, but is not limited to, cyclophosphamide, methotrexate, fluorouracil, paclitaxel, doxorubicin, tamoxifen and combinations thereof); prevention and treatment of bone loss in HIV patients associated with lipodsytrophy and treatment with antiviral drugs; prevention of the calcification of soft tissues (i.e., kidneys and other organs); prevention of the calcification
- the compounds of this invention increase bone formation and are therefore of value in the treatment of any of these conditions.
- Example 22 The procedure described in the Example 22 was followed, using 4-hydroxy-3-methoxy-5- methylbenzaldehyde (1.16 g, 6.6 mmol). The crude compound obtained was purified by flash column chromatography (SiO 2 , 98/2 AcOEt/MeOH). An amount of 0.93 g (2.7 mmol, 41 % yield) of the title compound was obtained.
- Example 7 Dimethyl 4-(5-tert-butyl-2-hydroxy-3-methoxyphenyl)-l,l-dimethyl-2-oxo-3- buten-1 -yl-phosphonate
- the chloroform phase was separated, the aqueous phase further extracted with fresh chloroform, the combined chloroform phases were dried, evaporated to dryness.
- the residue was purified by column chromatography (SiO2, dichloromethane (DCM)) to give 4.0 g (12.5 mmol, 62%) of ethyl 3,5-di-tert-butyl-2-methoxycinnamate.
- diethyl methylphosphonate (3.04 g, 19.97 mmol) was added at -78° to a solution of n-butyllithium (12.5 ml of a 1.6 M solution in hexane, 19.97 mmol) in 70 ml anhydrous THF.
- the reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion.
- the mixture was again cooled to -78° and a solution of ethyl 3,5-di-tert-butyl-2-methoxycinnamate (2.54 g, 7.99 mmol) in 20 ml dry THF was added.
- Methyl iodide (2.7 ml, 6.1 g, 43 mmol) was added dropwise to a mixture of 3,5-di-tert- butyl-2-hydroxybenzaldehyde (5.0 g, 21.3 mol), potassium carbonate (4.4 g, 32 mmol), tetra-n- butylammonium bromide (0.69 g, 2.1 mmol) dissolved in 100 ml of 2-butanone and the resulting mixture was refluxed for 3 h. Further portions of methyl iodide were added (4 X 3 ml) at regular intervals and refluxing was resumed to complete the conversion.
- the chloroform phase was separated, the aqueous phase further extracted with fresh chloroform, the combined chloroform phases were dried, evaporated to dryness.
- the residue was purified by column chromatography (SiO2, AcOEt/MeOH 9/1) to give 4.7 g (16.3 mmol, 71%) of ethyl 3,5- di-tert-butylcinnamate.
- dimethyl methylphosphonate (2.37 g, 19 mmol) was added at -78°C to a solution of n-butyllithium (12 ml of a 1.6 M solution in hexane, 19.2 mmol) in 50 ml anhydrous THF.
- the reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion (slight turbidity).
- a solution of ethyl 3,5-di-tert-butylcinnamate (2.2 g, 7.64 mmol) in 5 ml dry THF was added. The resulting mixture was left to stir at room temperature (25°C) for 4 h.
- diethyl methylphosphonate (3.3 g, 21.7 mmol) was added at - 78° to a solution of n-butyllithium (13.6 ml of a 1.6 M solution in hexane, 21.7 mmol) in 75 ml anhydrous THF.
- the reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion.
- the mixture was again cooled to -60° and a solution of ethyl 3,5- di-tert-butylcinnamate (2.5 g, 8.68 mmol) in 20 ml dry THF was added.
- the resulting orange- colored mixture was left to stir at room temperature (25°C) for 2 h.
- n-Butyllithium (11.5 ml of a 1.6 M solution in hexane, 18.4 mmol) was added to 40 ml of THF cooled to -78°C, followed by dimethyl ethylphosphonate (3.94 g, 28.5 mmol). The resulting solution was stirred for 15 min at -78°C, then a solution of ethyl 3,5-di-tert- butylbenzoate (2.5 g, 9.6 mmol) in 10 ml THF was added and the resulting reaction was left to gradually reach room temperature overnight. A saturated ammonium chloride solution was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of ethyl ether.
- Example 33 Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl )-2-oxo-3- buten-1-yl phosphonate
- diethyl methylphosphonate (3.8 g, 25 mmol) was added at - 78°C to a solution of n-butyllithium (25 ml of a 1.6 M solution in hexane, 40 mmol) in 25 ml anhydrous THF.
- the reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion (slight turbidity).
- a solution of ethyl 3-[3-tert-butyl-4-hydroxy- 5,6,7,8-tetrahydrona ⁇ hthyl]-acrylate (2.0 g, 8.0 mmol) in 10 ml dry THF was added.
- diethyl ethylphosphonate (2.89 g, 17.38 mmol) was added at -78°C to a solution of n-butyllithium (10.9 ml of a 1.6 M solution in hexane, 17.38 mmol) in 75 ml anhydrous THF.
- the reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion.
- a solution of ethyl 3-[3-tert-butyl-4-hydroxy-5,6,7,8- tetrahydronaphthyl] -acrylate (2.1 g, 6.95 mmol) in 10 ml dry THF was added.
- Example 39 Dimethyl 4- (3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl )-2-oxo-3- buten-1-yl phosphonate
- the chloroform phase was separated, the aqueous phase further extracted with fresh chloroform, the combined chloroform phases were dried, evaoparted to dryness.
- the resisue was purified by column chromatography (SiO2, AcOEt/hexane 5/95) to give 4 g (12.6 mmol, 70%) of ethyl 3-[3-tert-butyl-4-methoxy- 5,6,7,8-tetrahydronaphthyl]-acrylate.
- dimethyl methylphosphonate (2.5 g, 20 mmol) was added at -78°C to a solution of n-butyllithium (21 ml of a 1.6 M solution in hexane, 33 mmol) in 25 ml anhydrous THF.
- the reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion (slight turbidity).
- a solution of ethyl 3-[3-tert-butyl-4-methoxy- 5,6,7,8-tetrahydronaphthyl]-acrylate (2.0 g, 6.6 mmol) in 10 ml dry THF was added.
- diethyl methylphosphonate (2.8 g, 18 mmol) was added at - 78°C to a solution of n-butyllithium (19 ml of a 1.6 M solution in hexane, 30 mmol) in 25 ml anhydrous THF.
- the reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion.
- a solution of ethyl 3-[3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthyl]-acrylate (1.9 g, 6.0 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir at room temperature (25°C) for 4 h.
- Example 41 Dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l- dimethyl-2-oxo-3-buten-l -yl-phosphonate t-Bu
- Methyl iodide (5.6 ml, 0.09 mol) was added dropwise to a mixture of 3-tert-butyl-4- hydroxy-5,6,7,8-tetrahydronaphthaldehyde (7.0 g, 0.031 mol), potassium carbonate (8 g, 0.06 mol), tetra-n-butylammonium bromide (0.8 g, 0.002 mol) dissolved in 10 ml of 2-butanone and the resulting mixture was refluxed for 3 h. The cooled mixture was filtered, the filtrate was concentrated under vacuum and partitioned between dichloromethane and water. Evaporation of the dried organic phase gave 7.3 g (0.030 mmol, 95% crude) of 3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthaldehyde.
- Example 45 Dimethyl 4-(3-tert-butyI-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l- cyclopentyIiden-2-oxo-3-buten-l-yl-phosphonate t-Bu
- Example 46 Dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2- oxo-3-buten-l-yl-phosphonate
- diethyl ethylphosphonate (2.63 g, 15.8 mmol) was added at - 78°C to a solution of n-butyllithium (9.9 ml of a 1.6 M solution in hexane, 15.8 mmol) in 25 ml anhydrous THF.
- the reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion.
- a solution of ethyl 3-[3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthyl] -acrylate (2.0 g, 6.3 mmol) in 10 ml dry THF was added.
- Example 50 Dimethyl 4-(3-benzyl-4-hydroxy-l-naphthyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate
- Example 51 Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-l- butyl-phosphonate
- the title compound was obtained in 40% yield by reducing a solution of dimethyl 4-(3- tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l-yl-phosphonate (0.20 g) over a suspension of Pd/C (0.15 g) in ethyl acetate.
- Example 52 Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l- dimethyl-2-oxo-l-butyl-phosphonate t-Bu
- the title compound was obtained in 80% yield by reducing a solution of dimethyl 4-(5- tert-butyl-2-hydroxy-3-methoxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate (0.20 g) over a suspension of Pd/C (0.15 g) in ethyl acetate.
- Example 54 Dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-dimethyl-2-oxo-l-butyl- phosphonate
- HMGR levels Quantification of HMGR levels by Immunoblotting HeLa cells (ATCC) were seeded in 6 wells plates (8.10 5 cells per well) in DMEM contaimng 10% fetal calf serum (FCS) and grown for 1 day. Then, the medium was replaced by DMEM without FCS and the cells were further grown for 16 h. Products were tested at 1 and 10 ⁇ M final concentrations; they were added as 1000-fold concentrated stock solutions in 50% EtOH and 50% DMSO.
- FCS fetal calf serum
- HMG- CoA reductase levels were analysed by subsequent immunoblotting using mouse A9 mAbs (hybridoma cells CRL-1811; ATCC). Bound A9 antibodies were revealed by goat anti-mouse IgG peroxidase-coupled antibodies (Sigma) and SuperSignal West Dura Extended Duration Substrate (Pierce) followed by autoradiography.
- Compounds (I) were tested at two different concentrations: 1 and 10 ⁇ M.
- the relative potencies of Compounds (I) for decreasing HMG-CoA reductase were expressed as approximative % change of samples treated with 10 ⁇ M test compoxxnds of Formula (I) over control samples.
- HMG-CoA reductase levels were estimated by comparing samples from treated cells with samples from non-treated cells.
- ++++ is 100% decrease in HMGR levels at 10 and at 1 ⁇ M +++ is 100% decrease in HMGR levels at 10 ⁇ M /50-99% at 1 ⁇ M ++ is 50-99% decrease in HMGR levels at 10 ⁇ M / 0-50% at 1 ⁇ M + is 10-49% decrease in HMGR levels at 10 ⁇ M / 0% at 1 ⁇ M (+) is 1-10% decrease in HMGR levels at 10 ⁇ M / 0% at 1 ⁇ M.
- mice Male OF1 mice (Charles River, France), weighing ca 30g were divided into groups of 6 animals. Animals were maintained on a 12 h- 12 h light cycle and were fed ad libitum with UAR A03 (France) chow. The calcium and phosphorus contents of the food were respectively 0.8% and 0.6%). Food consumption and body weight were measured on a weekly basis.
- Control group received standard chow and Treated groups received test compounds mixed with the diet, at the required concentration to the targeted dose level. Doses used varied from 12.5 mg/kg to 100 mg/kg. Active compounds showed activity around the minimal dose 12.5 mg/kg.
- the pQCT technique is a highly sensitive method that allows the monitoring of bone loss and bone gain over time in a non-invasive manner. It has been validated for measuring bone parameters in mice treated with bone anabolic agents such as the hormone PTH and the antiresorptive bisphosphonic acids (see Feretti et al, 1996 and Gasser, 1995). It has been shown previously that the pQTC technique employed correlates with bone dry weight.
- Table 2 shows that two representative compounds of Formula (I) markedly increase bone formation: at 12.5mg/kg, Compounds 52 and 37 increased vertebra trabercular density by respectively 11 and 26 %; furthermore at 50 mg/kg Compound 37 increased the vertebra density by 57 %.
- the compounds of the present invention are thus useful in pharmaceutical formulations for the prevention and treatment of diseases where bone growth is necessary.
- Table 2 - In Vivo effect of Compounds of Formula (I), wherein Y is O, on Mouse Bone
- a tablet composition containing a compound of formula (I) is prepared by mixing and compressing in a tablet making machine the flowing ingredients: 200 mg compound of formula (I); 200 mg lactose; and 20 mg magnesium stearate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides substituted ketophosphonate compositions of matter, pharmaceutical compositions and methods of use of such compositions for the treatment and/or prevention of bone diseases.
Description
DESCRIPTION
SUBSTITUTED KETOPHOSPHONATE COMPOUNDS HAVING BONE ANABOLIC
ACTIVITY
FIELD OF INVENTION
The present invention relates to the use of novel substituted ketophosphonate compounds in the treatment and/or prevention of bone diseases requiring, such as osteoporosis, through enhanced bone anabolic activity.
BACKGROUND OF THE INVENTION
Bone remodelling and repair is a tightly regulated process that continues throughout a person's lifetime. Bone formation requires the activity of the osteoblasts, the bone forming cells, whereas bone resorption results from the action of the osteoclasts. Consequently, two therapeutic approaches toward bone mass manipulation are currently investigated, namely, prevention of bone resorption and stimulation of bone formation (bone anabolism).
A preferred approach for the prevention and/or treatment of bone diseases is to increase bone formation by stimulation of osteoblasts. However, the large majority of therapeutic agents which stimulate bone formation or inhibit bone turnover are hormones or derivatives of hormones (estrogens, anabolic steroids, calcitonin, parathyroid hormone, vitamin D) with numerous side effects resulting from their hormonal activities. Sodium fluoride, the old prophylatic for dental caries, is still the most widely used compound for the stimulation of bone formation. There is thus a need for new active compounds, preferably oral agents, that act by stimulating bone formation.
The bisphosphonic acids (BP; also known as diphosphonic acids) and their salts are a class of compounds that are cytotoxic to osteoclasts and act to prevent bone resorption. These compounds have no effect on osteoblasts. Anti-resorptive bisphosphonic acids are currently used for the treatment of various bone diseases such as osteoporosis, hypercalcemia due to malignancies and inhibition of tumor cell metastasis in bone tissue. Despite their proven pharmacologic efficacy, the clinical utility of bisphosphonic acids is limited by their very low oral bioavailability and their gastrointestinal toxicity.
It has also been reported that statins have bone anabolic activity and prevent fractures in patients. These compounds, known to be HMG-CoA reductase inhibitors, were found to increase the synthesis of bone morphogenic protein 2 (BMP -2), a growth factor that triggers osteoblast differentiation to form new bone (see Mundy et al., 1999). The mechanism of the effect of statins on bone anabolism remains to be elucidated.
Although the fact that HMG-CoA reductase inhibitors induce BMP-2 synthesis and osteoblastic differentiation is well established, there remains a need to identify compounds with bone anabolic activity that are not solely competitive inhibitors of HMG-CoA reductase, as this class of inhibitors is characterized by a high degree of toxicity when systemically available. Furthermore, current inhibitors of HMG-CoA reductase were designed to target the liver and induce hypocholesterolemia, and are also known to trigger a positive feed-back resulting in the upregulation of the large majority of genes involved in isoprenoids and cholesterol synthesis. Thus, these compounds have significant drawbacks in the context of the treatment of bone diseases.
Consequently, it would be useful to identify synthetic compounds which decrease HMG- CoA reductase levels leading to bone anabolic activity.
SUMMARY OF THE INVENTION
The Applicants have now found that substituted phosphonates of formula (I), as set out below, have bone anabolic activity and are thereby useful in the treatment of bone diseases. One aspect of the invention are substituted phosphonate compounds of the formula (I): z^
Ar - ■ L - ■ p. ( i )
\ z* wherein Ar is:
and X° is H, OH or a straight or branched d to C6 alkoxy group,
X1, X2 and X3 are independently H, OH, a straight, branched or cyclic Cι-C6 alkyl or alkoxy group;
or X , X or X , X together may form a Cχ - Cg optionally substituted alkylidenoxy or alkylidenedioxy group; with the proviso that X is H when X is H and X and X are independently straight or branched C\ - C<5 alkyl groups; X4, X5, X6 are independently H, a straight or branched Ci - C6 alkyl group; q is zero or 1 ;
X7 is H, a straight or branched Ci - C8 alkyl or alkoxy group, or an optionally substituted benzyl group; Y is O or S; Z 1 and Z2 are independently OR 1 or NR 2 R 3 , where R 1 , R 2 , and R 3 are independently H or a
1 2 straight or branched Cj - Cg alkyl group, or Z , Z together may form a C. - Cg alkylidenedioxy group; and
L is a saturated or unsaturated - Cπ alkylene chain in which one or more of the methylene groups can be replaced by a sulfur atom, an oxygen atom, a carbonyl group wherein optionally one or more methylene groups can be substituted by one or more halogen atoms (F, Cl or Br), -Cδ alkyl, an optionally substituted aryl or heteroaryl group. The present invention also encompasses pharmaceutically acceptable salts, solvates and hydrates of compounds of formula
0).
In various embodiments of the present invention, L is -A-C(O)-B-, wherein "-A-" is a direct bond, -CH=C(R4)-,-CH2-C(R4)(R5)-, -C(R4)(R5)-, -O-C(R4)(R5)-, -S-C(R4)(R5)-, where R4,R5 are independently or different are, H, halogen (F, Cl, Br), -Q straight or branched alkyl, an optionally substituted aryl or heteroaryl,
"-B-" is -C(R6)(R7)- where R6,R7 identical or different are H, Halogen (F, Cl, Br), Cι-C6 straight or branched alkyl, an optionally substituted aryl or heteroaryl, or R6 and R7 can form a ring of C3-O7 carbon atoms.
The term "alkyl" and "alkoxy" as used herein in relation to X°, X1, X2, X3, X6, R1, R2, R3, R4 and R5 means as indicated saturated straight, branched or cyclic substitutents, i.e., straight or branched -(CnH n+1) or -O(CnH2n+1) or cyclic -(CnH n-ι)- or -O-(C„H2n-ι)-, and a^so includes halogenated alkyl and alkoxy groups and derivatives thereof, such as fluoro-substituted groups, fluorohydroxy substituted groups wherein the degree of halogenation ranges from a single halo substituent, e.g., -CH2F and -OCH2F, to perhalo-substituted alkyl and alkoxy groups, e.g., -CF and -OCF3.
In some embodiments, Ar is:
wherein X° is H, OH, OMe, X3 is H, OH, Me, OMe, X1 and X2 are independently a straight or branched Ci - C6 alkyl, a straight or branched Ci - C6 alkoxy group; with the proviso that X° is H when X3 is H, and X1 and X2 are independently a straight or branched Ci - C6 alkyl groups;
Y is O; Z1 and Z2 are the same and are OR1 wherein R1 is methyl, ethyl or isopropyl;
L is CH=C(R4)-CO-C(R6R7), or -COC(R6)(R7)-wherein R4, R6 and R7 are as previously defined, and in some embodiments L is CH=CH-CO-C(CH3)2, CH=CH-CO-CH2, CH=CH-CO- C(CH3)(F), CH=CH-CO-C(F)2, or CO-CH2, CO-C(CH3)2, CO-C(CH3)(F), CO-C(F)2. In another embodiment, Ar is:
wherein X° is H, OH, OMe; X4 is H, a straight, branched or cyclic to C8 alkyl or alkoxy group, more preferably X4 is a tert-butyl group;
X5 and X6 are indepdently H, a C1-C4 alkyl group, more preferably X5 and X6 are H; q is zero or 1, more preferably q is 1;
Y is O; Z1 and Z2 are the same and are OR1 wherein R1 is methyl, ethyl or isopropyl; L is CH=C(R4)-CO-C(R6R7), or -COC(R6)(R7)-wherein R4, R6 and R7 are as previously defined, and in some embodiments L is CH=CH-CO-C(CH3)2, CH=CH-CO-CH2, CH=CH-CO-
C(CH3)(F), CH=CH-CO-C(F)2, or CO-CH2, CO-C(CH3)2, CO-C(CH3)(F), CO-C(F)2.
In a further embodiments Ar is:
wherein X° is H, OH, SH, OMe, SMe group;
X is H, a straight or branched C\ - C8 alkyl or alkoxy group, preferably a t-butyl group or an optionally substituted benzyl group;
Y is O;
Z and Z2 are the same and are OR1 wherein R1 is methyl, ethyl or isopropyl;
L is CH=C(R4)-CO-C(R6R7), or -COC(R6)(R7)-wherein R4, R6 and R7 are as previously defined, and in some embodiments L is CH=CH-CO-C(CH3)2,CH=CH-CO-CH2, CH-CH-CO- C(CH3)(F), CH=CH-CO-C(F)2, or CO-CH2, CO-C(CH3)2, CO-C(CH3)(F), CO-C(F).
In various further embodiments, the novel substituted phosphonate compound of formula
(I) is selected from the group consisting of:
dimethyl 4-(3-methoxy-5-methyl-4-hydroxyphenyl)-l, l-dimethyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3,5-dimethoxy-4-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3 ,4,5-trimethoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3-buten- 1 -yl-phosphonate; dimethyl 4-(4,5-dimethoxy-3-hydroxyphenyl)- 1 , 1 -dimethyl-2-oxo-3-buten- 1 -yl-phosphonate; dimethyl 4-(3,5-diethoxy-4-hydroxyphenyl)-l , 1 -dimethyl-2-oxo-3-buten-l -yl-phosphonate; dimethyl 4-(4-hydroxy-3-methoxy-5-n-propylphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(5-tert-butyl-2-hydroxy-3-methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3-buten- 1 -yl- phosphonate; dimethyl 4-(3 -cyclopentyloxy-4-methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl-phosphonate; dimethyl 4-(3,5-di-cyclopentyl-4-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl- phosphonate; diethyl 2-(3 ,4,5 -trimethoxyphenyl)- 1 , 1 -dimethyl-2-oxo-ethylphosphonate; dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-bu1yl-2-hydroxvphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-diethyl-2-oxo-3-buten-l-yl phosphonate;
diethyl 4-(3 ,5 -di-tert-butyl-2-hydroxyphenyl)- 1 , 1 -diethyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-cyclopentyliden-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3 , 5 -di-tert-butyl-2-hydroxyphenyl)- 1 , 1 -cyclopentyliden-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 4-(3 ,5 -di-tert-butyl-2-hydroxyphenyl)- 1 -fluoro- 1 -methyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3 ,5 -di-tert-butyl-2-methoxyphenyl)-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3 ,5 -di-tert-butyl-2-methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl pho sphonate; diisopropyl 4-(3 , 5 -di-tert-butyl-2-methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3-buten- 1 -yl phosphonate; dimethyl 4-(3 ,5-di-tert-butyl-2-methoxyphenyl)- 1 -methyl-2-oxo-3-buten- 1 -yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l-methyl-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3 ,5 -di-tert-butyl-2-methoxyphenyl)- 1 -fluoro- 1 -methyl-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 4-(3 ,5 -di-tert-butyl-2-methoxyphenyl)- 1 -fluoro- 1 -methyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-difluoro-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-difluoro-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3 ,5 -di-tert-butyl-2-methoxyphenyl)- 1 , 1 -diethyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3 ,5 -di-tert-butyl-2-methoxyphenyl)- 1 , 1 -cyclopentyliden-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-methyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-dimethyl-2-oxoethylphosphonate; dimethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-fluoro-l-methyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-fluoro-l-methyl-2-oxoethylphosphonate; dimethyl 4-(3,5-di-tert-butylphenyl)-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butylphenyl)-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butylphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butyl-phenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3 ,5-di-tert-butylphenyl)- 1 -ethyl- 1 -methyl-2-oxo-3-buten- 1 -yl phosphonate; dimethyl 4-(3 ,5-di-tert-butylphenyl)- 1 , 1 -diethyl-2-oxo-3-buten- 1 -yl phosphonate;
dimethyl 4-(3,5-di-tert-butylphenyl)-l,l-cyclopentyliden-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butylphenyl)-l,l-fluoro-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3 , 5-di-tert-butyl-phenyl)- 1 , 1 -fiuoro-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 2-(3,5-di-tert-butylphenyl)-l-methyl-2-oxoethylphosphonate; diethyl 2-(3 , 5-di-tert-butyl-phenyl)- 1 -methyl-2-oxoethylphosphonate; dimethyl 2-(3 ,5-di-tert-butylphenyl)- 1 , 1 -dimethyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butyl-phenyl)-l,l-dimethyl-2-oxoethylphosphonate; dimethyl 2-(3 ,5-di-tert-butylphenyl)- 1 -fluoro- 1 -methyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butylphenyl)-l-fluoro-l-methyl-2-oxethylphosphonate; dimethyl 2-(3,5-di-tert-butylphenyl)-l,l-difluoro-2-oxoethylphosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate; diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)- 1 , l-dimethyl-2-oxo-3 -buten- 1 -yl- phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo-3- buten- 1 -yl-phosphonate; diethyl 4-(3 -tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)- 1 -fluoro- 1 -methyl-2-oxo-3-buten- 1 -yl-phosphonate; αιmethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaρhthyl)-l-ethyl-l-methyl-2-oxo-3-buten-
1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-diethyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetralιydronaphthyl)-l,l-cyclopentylidene-2-oxo-3- buten- 1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl-2-oxo-3-buten-l-yl-phosphonate;
dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate; diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo-3-buten-l-yl- phosphonate; diisopropyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo-3- buten- 1 -yl-phosphonate; diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo-3-buten-
1 -yl-phosphonate; dimethyl 4-(3 -tert-butyl-4-methoxy-5,6,7, 8-tetrahydronaphthyl)- 1 -ethyl- 1 -methyl-2-oxo-3 - buten-1-yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-diethyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-cyclopentylidene-2-oxo-3- buten- 1 -yl-phosphonate; diethyl 2-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxoethyl phosphonate; diethyl 2-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo- ethylphosphonate; dimethyl 4-(3-tert-butyl-5,5-dimethyl-4-hydroxy-5,6,7,8-tetrahydro-l-naphthyl)-l,l-dimethyl-2- oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy- 1 -naphthyl)- 1 , 1 -dimethyl-2-oxo-3-buten- 1 -yl-phosphonate; dimemyl 4-(3-benzyl-4-hydroxy-l-naphthyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)- 1 , 1 -dimethyl-2-oxo- 1 -butyl-phosphonate; dimethyl 4-(5-tert-butyl-2-hydroxy-3-methoxyphenyl)- 1 , 1 -dimethyl-2-oxo- 1 -butyl-phosphonate; and dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)- 1 , 1 -dimethyl-2-oxo-l -butyl- phosphonate.
Embodiments also encompass pharmaceutical compositions of the substituted phosphonate compounds of formula (I) comprising a pharmaceutically acceptable carrier.
Another aspect of the present invention is a method of treating or preventing a bone disease or pathology, comprising administering to a subject in need of such treatment an amount effective to stimulate bone formation of a substituted phosphonate compound of formula (I).
In some embodiments, the bone disease or pathology is osteoporosis, Paget's disease, bone fracture, hormone-induced bone pathologies, hyperparathyroidism, peridontal disease, post- plastic surgery, post-prosthetic joint surgery, post-dental implantation, hypercalcemia secondary to malignancies or hyperparathyroidism, a condition arising from hypercalcemia, including calcification of soft tissue (e.g., kidney, vessel walls and heart values), calcification of surgical implants and calcification of arteries (e.g., due to late stage atherosclerosis). In some embodiments, the subject is characterized by a condition selected from the group consisting of osteoporosis, Paget's disease, bone fracture or deficiency, drug and hormone-induced bone pathologies (e.g., corticoids, retinoids and vitamin D3 induced bone pathologies), hype arathyroidism, periodontal disease or defect, post-plastic surgery, post-prosthetic joint surgery post-dental implantation, metastasis of cancer cells in bones, including osteolytic or osteoplastic bone metastasis, tumoral osteolysis, and hypercalcemia, wherein said hypercalcemia is secondary to malignancies.
In some embodiments, the method further comprises administration to the subject an effective amount of a bone resorption inhibitor, which may be alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, S-12911, raloxifene, simvastatin, atorvastatin, cerivastatin, vitamin D or calcitonin.
DETAILED DESCRIPTION OF THE INVENTION
I. Bone Anabolic Substituted Phosphonate Compounds
"While the present invention is not bound by any particular theory, it is believed that the compounds of formula (I) modify bone formation by affecting the mevalonate/isoprenoid/cholesterol (MIC) pathway. The administration of statins, competitive inhibitors of HMG-CoA reductase (a rate-limiting step in cholesterol synthesis), results in increased bone morphogenetic protein-2 (BMP-2) levels and thereby stimulates osteoblast differentiation. Apart from cholesterol, the MIC pathway also provides isoprenoids, e.g., farnesylpyrophosphate and geranylgeranylpyrophosphate, compounds that serve as important lipid anchors for the post-translational modification of a variety of cell signalling proteins such as Rap, Ras and Rho. These signalling proteins, when anchored in the osteoclast cell membrane
by a lipid prenyl group, regulate the osteoclast cell processing required for active bone resorption, e.g., cytoskeleton organization and membrane ruffling. The discovery that the compounds of formula (I) decrease the level of HMG-CoA reductase, tends to indicate that these compounds may be useful for the treatment of bone diseases, as verified by their bone anabolic activity in animal models
Pharmaceutically acceptable salts for use in the present invention include those described by Berge et al. (1977). Such salts may be formed from inorganic and organic acids. Representative examples thereof include salts formed from alkali metals such as potassium and sodium. Since the compounds of the present invention are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I). Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.
When some of the compounds of this invention are allowed to crystallise or are recrystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, some of the compounds of this invention maybe crystallised or recrystallised from solvents containing water. In such cases water of hydration may be formed. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. In addition, different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products. This invention includes within its scope all polymorphic forms of the compounds of formula (I).
II. Formulations and Administration
The compounds of formula (I) can be administered by any of a variety of routes. Thus, for example, they can be administered orally, or by delivery across another mucosal surface (for example across the nasal, buccal, bronchial or rectal mucosa), transdermally, or by injection (for example intradermal, intraperitoneal, intravenous or intramuscular injection).
When the compounds are intended for oral administration, they can be formulated, for example, as tablets, capsules, ovules, granules, pills, lozenges, powders, solutions, emulsions,
syrups, elixirs, suspensions, or any other pharmaceutical form suitable for oral administration. Oral dosage forms can, if desired, be coated with one or more release delaying coatings to allow the release of the active compound to be controlled or targeted at a particular part of the enteric tract. Tablets and other solid or liquid oral dosage forms can be prepared (e.g., in standard fashion) from the compounds of formula (I) and a pharmaceutically acceptable solubilizer, diluent or carrier. Examples of solubilizers, diluents or carriers include sugars such as lactose, starches, cellulose and its derivatives, powdered tracaganth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols such as glycerol, propyleneglycol and polyethyleneglycols, alginic acids and alginates, agar, pyrogen free water, isotonic saline, phosphate buffered solutions, and optionally other pharmaceutical excipients such as disintegrants, lubricants, wetting agents such as sodium lauryl sulfate, coloring agents, flavoring agents and preservatives, etc.
Capsules can be of the hard or soft variety and can contain the active compound in solid, liquid or semisolid form. Typically such capsules are formed from gelatine or an equivalent substance and can be coated or uncoated. If it is desired to delay the release of the active compound until the capsule has passed through the stomach and into the intestine, the capsule can be provided with a pH sensitive coating adapted to dissolve at the pH found in the duodenum or ileum. Examples of such coatings include the Eudragits, the uses of which are well known. Formulations for injection will usually be made up of the appropriate solubilizers such as detergents which may also include compounds and excipients such as buffering agents to provide an isotonic solution having the correct physiological pH. The injectable solutions are typically pyrogen-free and can be provided in sealed vials or ampoules containing a unit dose of compound. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can
be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatine capsule.
Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
Preferably the composition is in unit dose form such as a tablet or capsule.
The choice of form for administration as well as effective dosages will vary depending, inter alia, on the condition being treated. The choice of mode of administration and dosage is within the ability of the person skilled in the art.
A unit dosage form of the compounds of the invention typically will contain from 0.1% to 99% by weight of the active substance, more usually from 5% to 75% of the active substance.
By way of example, a unit dosage form can contain from 1 mg to 1 g of the compound, more usually from 10 mg to 500 mg, for example between 50 mg and 400 mg, and typically in doses of l00 mg to 200 mg.
Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The compounds of the invention will be administered in amounts that are effective to provide the desired therapeutic effect. The concentrations necessary to provide the desired therapeutic effect will vary according to among other things the precise nature of the disease, the size, weight and age of the patient and the severity of the disease.
The doses administered will preferably be non-toxic to the patient, although in certain circumstances the severity of the disease under treatment may necessitate administering an amount of compound that causes some signs of toxicity.
Typically, the compounds of the invention will be administered in amounts in the range 0.01 mg/kg tolOO mg/kg body weight, more preferably 0.1 g kg to 10 mg kg body weight and particularly 1 mg kg to 5 mg kg body weight.
The pharmaceutically acceptable compounds of the invention will normally be administered to a subject in a daily dosage regimen. For an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Thus, for an average human of 70 kg weight, a typical daily dosage of the compounds of the invention would be in the range of 70 mg to 700 mg. Such a dosage can be administered, for example from two to four times daily. Ultimately however, the size of the doses administered and the frequency of administration will be at the discretion and judgement of the physician treating the patient.
The compounds of the invention may also be administered in combination with an effective amount of a bone resorption inhibitor. Bone resorption inhibitors are those agents known in the art to inhibit the absorption of bone and include, but are not limited to the following classes of compounds: bisphosphonic acids, such as alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, and S-12911; Selective Estrogen Receptor Modulators (SERMs), such as: raloxifene; HMG-CoA reductase inhibitors, such as simvastatin, atorvastatin and cerivastatin; steroid hormones, such as Vitamin D; and polypeptide hormones, such as calcitonin. Dosage ranges and regimens for bone resorption inhibitors are those which are known in the art. In particular, when a bisphosphonic acid is employed, a daily dosage of 2.5 to 100 mg may be used. In accordance with the method of the present invention, the components of a combination of the compounds of the present invention and bone resorption inhibitors can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. According to the instant invention, the term "administering" is to be understood as embracing all such regimes of simultaneous or alternating treatment and the scope of combinations of the compounds of this invention and bone resorption inhibitors includes in principle, any combination useful for inhibiting bone loss and building new bone. Disease states which could benefit from increasing bone formation include, but are not limited to: osteoporosis; prevention and accelerated repair of bone fracture; prevention and treatment of metastasis of cancer cells in bone; prevention and treatment of osteolytic bone lesions; prevention and treatment of osteoblastic bone metastasis; prevention and treatment of increased bone remodeling, bone hypertrophy and abnormal bone structure (i.e., Paget's
disease); prevention and treatment of bone loss associated with cancer therapies (e.g., bone loss associated with the treatment of gonadotropin-releasing hormone agonists for prostate cancer and bone loss associated with chemotherapy for breast cancer, wherein such chemotherapy includes, but is not limited to, cyclophosphamide, methotrexate, fluorouracil, paclitaxel, doxorubicin, tamoxifen and combinations thereof); prevention and treatment of bone loss in HIV patients associated with lipodsytrophy and treatment with antiviral drugs; prevention of the calcification of soft tissues (i.e., kidneys and other organs); prevention of the calcification of surgical implants (i.e., natural and artificial organs such as cardiac valves); treatment of patients suffering from calcified soft tissues and calcified surgical implants; prevention and treatment of calcification and calcified arteries (arteriosclerosis); hypercalcemia secondary to an increase in bone resorption; hypercalcemia secondary to malignancies; tumoral osteolysis; drug and hormonal (e.g., corticoids, retinoid, vitamin D3) induced bone pathologies; bone remodelling (plastic surgery); operative repair of cartilage; dental surgery; and orthodontic pathologies.
The compounds of this invention increase bone formation and are therefore of value in the treatment of any of these conditions.
EXAMPLES OF THE INVENTION
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following specific examples are intended merely to illustrate the invention and not to limit the scope of the disclosure or the scope of the claims in any way whatsoever.
Example 1: Dimethyl 4-(3-methoxy-5-methyl-4-hydroxyphenyl)-l,l-dimethyl-2-oxo-3- buten-1-yl-phosphonate
The procedure described in the Example 22 was followed, using 4-hydroxy-3-methoxy-5- methylbenzaldehyde (1.16 g, 6.6 mmol). The crude compound obtained was purified by flash column chromatography (SiO2, 98/2 AcOEt/MeOH). An amount of 0.93 g (2.7 mmol, 41 % yield) of the title compound was obtained.
MS: m e = 342: M+, 232: M+ - HPO3Me2, 191 (100%): M+- CMe2(PO3Me2) NMR: (CDC13) δ = 7.62 (d, J = 16Hz, 1H): Ph-CH=CH 7.27 (d, J = 16Hz, 1H): Ph-CH=CH 7.06 and 6.95 (two m, total 2H): arom. H
6.0 (s, 1H): OH 3.93 (s, 3H): arom. O-CH3
3.79 (d, J = 11 Hz, 6H): P-O-CH3
2.27 (s, 3H): arom. CH3 1.51 (d, J = 16.5Hz, 6H): -C(CH3)2-P
Example 2: Dimethyl 4-(3,5-dimethoxy-4-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate
The procedure described in the preceding example was followed, using 3,5-di-methoxy-
4-hydroxybenzaldehyde (1.2 g, 6.6 mmol). The crude compound obtained was purified by flash column chromatography (SiO2, 98/2 AcOEt/MeOH). An amount of 0.56 g (1.6 mmol, 26 % yield) of the title compound was obtained.
MS: m/e = 358: M+, 248: M1" - HPO3Me2, 207 (100%): M+- CMe2(PO3Me2) NMR: (CDCI3) δ = 7.62 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.28 (d, J = 16Hz, 1H): Ph-CH=CH 6.85 (s, 2H): arom. H 5.9 (s, 1H): OH 3.94 (s, 6H): arom. O-CH3
3.79 (d, J = 11 Hz, 6H): P-O-CH3
1.52 (d, J = 16.5Hz, 6H): -C(CH3)2-P
Example 3: Dimethyl 4-(3,4,5-trimethoxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl- phosphonate
The procedure described in the preceding example was followed, using 3,4,5-tri- methoxybenzaldehyde (1.3 g, 6.6 mmol). The crude compound obtained was purified by flash column chromatography (SiO2, 98/2 AcOEt/MeOH). An amount of 1.12 g (3.1 mmol, 45 % yield) of the title compound was obtained.
MS: m/e = 372: M+ 262: M* - HPO3Me2, 221 (100%): M+- CMe2(PO3Me2) NMR: (CDC13) δ = 7.61 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.32 (d, J = 15.5Hz, 1H): Ph-CH=CH 6.83 (s, 2H): arom. H 3.91 and 3.89 (two s, total 9H): arom. O-CH3
3.79 (d, J = 11 Hz, 6H): P-O-CH3 1.52 (d, J = 16.5Hz, 6H): -C(CH3)2-P
Example 4: Dimethyl 4-(3,5-diethoxy-4-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl- phosphonate
The procedure described in the preceding example was followed, using 3,5-di-ethoxy-4- hydroxybenzaldehyde (1.4 g, 6.6 mmol). The crude compound obtained was purified by flash column chromatography (SiO , 98/2 AcOEt/MeOH). An amount of 1.6 g (4.1 mmol, 62 % yield) of the title compound was obtained.
MS: m/e = 386: M+, 276: M+ - HPO3Me2, 235 (100%): M+- CMe2(PO3Me2) NMR: (CDCI3) δ = 7.59 (d, J = 16Hz, 1H): Ph-CH=CH 7.26 (d, J = 16Hz, 1H): Ph-CH=CH
6.84 (s, 2H): arom. H
5.84 (s, 1H): OH
4.17 (q, J = 7Hz, 4H): arom. O-CH2-CH3
3.78 (d, J = 11 Hz, 6H): P-O-CH3
1.51 (d, J = 16.5Hz, 6H): -C(CH3)2-P
1.47 (t, J = 7Hz, 6H): arom. O-CH2-CH3
Example 5: Dimethyl 4-(4,5-dimethoxy-3-hydroxyphenyI)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate
The procedure described in the preceding example was followed, using 4,5-di-methoxy-3- hydroxybenzaldehyde (1.2 g, 6.6 mmol). The crude compound obtained was purified by flash column chromatography (SiO2, 98/2 AcOEt/MeOH). An amount of 0.72 g (2.0 mmol, 30 % yield) of the title compound was obtained. MS: m/e = 358: M+, 248: M+ - HPO3Me2, 207 (100%): M+- CMe2(PO3Me2) NMR: (CDCI3) δ = 7.57 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.28 (d, J = 15.5Hz, 1H): Ph-CH=CH 6.95 and 6.69 (two d, J = 2Hz, 2H): arom. H 6.15 (s, 1H): OH
3.92 (d, J = 11 Hz, 6H): P-O-CH3
3.81 and 3.79 (two s, 6H): arom. O-CH3
1.51 (d, J = 16.5Hz, 6H): -C(CH3)2-P
Example 6: Dimethyl 4-(4-hydroxy~3~methoxy-5-n-propylphenyl)-l,l-dimethyl-2-oxo-3- buten-l-yl-pho
The procedure described in the preceding example was followed, using 4-hydroxy-3- methoxy-5-n-propylbenzaldehyde (1.28 g, 6.6 mmol). The crude compound obtained was purified by flash column chromatography (SiO , 98/2 AcOEt/MeOH). An amount of 1.58 g
(4.27 mmol, 65 % yield) of the title compound was obtained.
MS: m/e = 370: M+, 260: M+ - HPO3Me2, 219 (100%): M+- CMe2(PO3Me2) NMR: (CDC13) δ = 7.63 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.27 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.05 and 6.97 (two d, J = 2H, 2H): arom. H 5.98 (s, 1H): OH 3.93 (s, 3H): arom. -CH3 3.79 (d, J = 11 Hz, 6H): P-O-CH3
2.62 (q, J = 7 Hz, 2H): arom. CH2-CH2-CH3
1.65 (sextet, J = 7 Hz, 2H): arom. CH2-CH2-CH3
1.51 (d, J = 16.5Hz, 6H): -C(CH3)2-P
0.97 (t, J = 7 Hz, 3H): arom. CH2-CH2-CH3
Example 7: Dimethyl 4-(5-tert-butyl-2-hydroxy-3-methoxyphenyl)-l,l-dimethyl-2-oxo-3- buten-1 -yl-phosphonate
To 25 ml dry THF kept at 0°C were added sequentially T1CI4 (2 ml, 18 mmol), 5-tert- butyl-2-hydroxy-3-methoxybenzaldehyde (1.4 g, 6.7 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (1.6 g, 7.92 mmol), N-methyl morpholine (2.5 ml, 26.4 mmol) then the reaction mixture was stirred for 1 h at room temperature. Work up was carried out by adding
100 ml of iced-water, extracting the resulting mixture with three portions of 100 ml chloroform,
washing the chloroform phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave an oil that was purified by flash column chromatography (SiO , 7/3
AcOEt/hexane). An amount of 1.79 g (4.7 mmol, 70 % yield) of the title compound was obtained. MS: m/e = 384: M+, 233: M+- CMe2(PO3Me2), 57: tBu+ NMR: (CDCI3) δ = 7.87 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.61 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.10 and 6.92 (2d, 2H): arom. H 6.20 (s, 1H): OH
3.93 (s, 1H): arom. O-CH3
3.80 (d, J = 11 Hz, 6H): P-O-CH3
1.52 (d, J = 16.5Hz, 6H): -C(CH3)2-P
1.32 (s, 9H): t-C4H9
Example 8: Dimethyl 4-(3-cyclopentyloxy-4-methoxyphenyl)-l,l-dimethyl-2-oxo-3-buten- 1-yl-phosphonate
To 50 ml dry THF kept at 0°C were added sequentially ΗCI4 (3.0 ml, 27.3 mmol), 3- cyclopentyloxy-4-methoxybenzaldehyde (2 g, 9.1 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (2.1 g, 10.9 mmol), N-methyl moφholine (3.0 ml, 52.4 mmol) then the reaction mixture was stirred for 1 h at room temperature. Work up was carried out by adding 100 ml of iced- water, extracting the resulting mixture with three portions of 100 ml diethyl ether, washing the ether phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave an oil that was purified by flash column chromatography (SiO2, pure AcOEt). An amount of 0.92 g (0.25 mmol, 26 % yield) of the title compound was obtained. MS: m/e = 396: M+, 177 (100%): M+- CMe2(PO3Me2) - cC5H9 NMR: (CDCI3) δ = 7.64 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.2 (dd, 1H), 7.10 (d, 1H) and 6.86 (s, 1H): arom. H
7.24 (d, J = 15.5Hz, 1H): Ph-CH=CH
3.88 (s, 3H): OCH3
3.79 and 3.78 (2d, J = 11 Hz, 6H): P-O-CH3
4.82 (septuplet, 2H), 2.0-1.8 (m, 4H), 1.88-1.80 (m, 4H) and 1.65-1.61 (m, 8H): cyclo
C5H9
1.52 (d, J = 16.7Hz, 6H): -C(CH3)2-P
Example 9: Dimethyl 4-(3,5-dicyclopentyl-4-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten- 1-yl-phosphonate
To 20 ml dry THF kept at 0°C were added sequentially TiC-4 (0.4 ml, 3.72 mmol), 3,5- di-cyclopentyl-4-hydroxybenzaldehyde (0.4 g, 1.55 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (0.4 g, 1.86 mmol), N-methyl morpholine (0.9 ml, 7.44 mmol) then the reaction mixture was stirred for 1 h at room temperature. Work up was carried out by adding 100 ml of iced-water, extracting the resulting mixture with three portions of 100 ml diethyl ether, washing the ether phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave an oil that was purified by flash column chromatography (SiO2, 7/3
AcOEt/hexane). An amount of 0.14 g (0.32 mmol, 21 % yield) of the title compound was obtained. MS: m/e = 434: M+ 283 (100%): M+- CMe2(PO3Me2) NMR: (CDCI3) δ = 7.66 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.31 (s, 2H): arom. H 7.42 (d, J = 15.5Hz, 1H): Ph-CH=CH ca 5.3: OH
3.84 and 3.78 (2d, J = 11 Hz, 6H): P-O-CH3
3.17 (quintet, 2H), 2.1-2.03 ( , 4H), 1.88-1.80 (m, 4H) and 1.75-1.61 (m, 8H): cyclo
C5H9
1.52 (d, J = 16.7Hz, 6H): -C(CH3)2-P
Example 10: Dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten- 1 -yl-phosphonate
To 30 ml dry THF kept at 0°C were added sequentially TiC_4 (2.9 g, 15.5 mmol), 3,5-di- tert-butyl-2-hydroxybenzaldehyde (1.55 g, 6.54 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (1.6 g, 7.83 mmol), N-methyl morpholine (2.5 ml, 3.12 g, 30.9 mmol) then the reaction mixture was stirred for 2h at 0°C. Work up as previously described and purification by flash column chromatography (SiO2, 98/2 CH2C12/MeOH) gave 0.87 g (2.2 mmol, 32 % yield) of the title compound. Recrystallization from a mixture of petroleum ether and dichloromethane gave a white solid, mp= 142-144°C.
MS: m/e= 410: M+, 259 (27%): M+- CMe2(PO3Me2), 57 : tBu+, 152 (100%): CHMe2(PO3Me2)+ NMR: (CDC13) δ - 7.92 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.35 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.37 and 7.30 (two d, J = 2Hz, 2H): arom. H
5.98 (broad s, 1H): phenol OH 3.80 (d, J = 11Hz, 6H): P-O-CH3 1.52 (d, 16.5Hz, 6H): -C(CH3)2-P 1.45 and 1.31 (two s, 9H each): t-C4H9
Example 11: Diethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate
To 30 ml dry THF kept at 0°C were added sequentially TiC_4 (7.79 g, 41.03 mmol), 3,5- di-tert-butyl-2-hydroxybenzaldehyde (4.0 g, 17.09 mmol), diethyl l,l-dimethyl-2- oxopropylphosphonate 4.55 g, 20.51 mmol), N-methyl morpholine (8.29 g, 82.05 mmol) then the reaction mixture was stirred for 2 h at 0°C. Work up as previously described and purification by
flash column chromatography (SiO , 98/2 CH2C12/MeOH) gave 0.87 g (1.96 mmol, 13 % yield) of the title compound. Recrystallization from a mixture of petroleum ether and dichloromethane gave a white solid, mp= 94-95°C.
MS: m/e = 438: M+, 259 (32%): M+- CMe2(PO3Et2), 180 (100%): CMe2(PO3Et2)+, 57: tBu+ NMR: (CDC13) δ = 7.89 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.37 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.36 and 7.29 (two d, J = 2Hz, 2H): arom. H 5.98 (broad s, 1H): phenol OH 4.19-4.12 (m, 4H): P-O- CH2-CH3
1.52 (d, 16.5Hz, 6H): -C(CH3)2-P 1.44 and 1.31 (two s, 9H each): t-C4H9 1.33 (t, J = 7Hz, 6H): P-O- CH2-CH3
Example 12: Diethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l-fluoro-l-methyl-2-oxo-3- buten-1-yl-phosphonate
To a suspension of sodium hydride (0.77g of a 60% suspension in mineral oil, 32.05 mmol) in 60 ml THF was added a solution of 3,5-di-tert-butyl-2-hydroxybenzaldehyde (3.0 g, 12.82 mmol) in 10 ml THF and the resulting mixture was stirred for 30 min at 0°C. 2- Methoxyethoxymethyl chloride (3.19 g, 25.64 mmol) was added dropwise and the resuting mixture was stirred for 4 h at room temperature. After hydrolysis by a saturated NH4C1 solution, the reaction mixture was partitioned between water and DCM. The dried organic phase was evaporated and the residue was purified by column chromatography (SiO2, DCM) to give 2.5 g of 3,5-di-tert-butyl-2-(2-methoxyethoxymethoxy) benzaldehyde (7.8 mmol, 61%).
To a suspension of sodium hydride (0.93g of a 60% suspension in mineral oil, 38.82 mmol) in 60 ml THF was added a solution of triethyl phosphonoacetate (3.48 g, 15.53 mmol) in 10 ml THF and the resulting mixture was stirred for 30 min at 0°C. 3,5-di-tert-butyl-2-(2- methoxyethoxymethoxy)benzaldehyde (2.5 g, 7.8 mmol) was added dropwise and the resuting mixture was stirred for 2 h at room temperature. After hydrolysis by a saturated NH4C1 solution, the reaction mixture was partitioned between water and DCM. The dried organic phase was
evaporated and the residue was purified by column chromatography (SiO2, 98/2 DCM/MeOH) to give 2.1 g of ethyl 3,5-di-tert-butyl-2-(2-methoxyethoxymethoxy)cinnamate (5.4 mmol, 68%). n-Butyllithium (9.6 ml of a 1.6 M solution in hexane, 15.31 mmol) was added to 80 ml of THF cooled to -78°C, followed by diethyl ethylphosphonate (2.54 g, 15.31 mmol). The resulting solution was stirred for 15 min at -78°C, then a solution of ethyl 3,5-di-tert-butyl-2-(2- methoxyethoxymethoxy) cinnamate (2 g, 5.10 mmol) in 10 ml THF was added and the resulting reaction was left to stir at -78°C for 1 h. A saturated NH4C1 solution was added, the separated THF phase was collected and the aqueous phase was extracted with DCM. The THF and DCM portions were pooled, reextracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 98/2 DCM/MeOH) to give 2.2 g (4.3 mmol, 82 %) of diethyl 4-[3,5-di-tert-butyl-2-(2-methoxyethoxymethoxy)phenyl]-l-methyl-2-oxo-3-buten- 1-ylphosphonate.
A solution of diethyl 4-[3,5-di-tert-butyl-2-(2-methoxyethoxymethoxy)phenyl]-l-methyl- 2-oxo-3-buten-l-ylphosphonate (1.1 g, 2.15 mmol) dissolved in 10 ml MeCN was added to a suspension of sodium ethoxide (0.31 g, 4.51 mmol) in 50 ml MeCN kept at 0°C, the reaction was left to stir for 15 min then l-(chloromethyl)-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (1.6 g, 4.51 mmol) was added portionwise and the reaction mixture was left to stir at room temperature for 15 min. Water was added, the mixture was extracted into DCM. The organic solution was extracted with brine, dried over MgSO4 and evaporated. The residue containing 1.1 g (2.07 mmol, 96% crude) of diethyl 2-[3,5-di-tert-butyl-4-(2- methoxyethoxymethoxy) phenyl] - 1 -fluoro- 1 -methyl-2-oxo-3 -buten- 1 -ylphosphonate.
A mixture containing the latter compound (0.45 g, 0.89 mmol) was dissolved in a mixture of TFA (1.19 g, 10.4 mmol) in 15 ml dichloromethane was stirred at room temperature for lh. A 10% sodium hydroxide solution was added until pH 6, the aqueous solution extracted with dichloromethane, dried and evaporated to dryness. Purification by column chromatography (SiO2, 8/2 Hexane/AcOEt) gave 0.28 g (0.63 mmol, 30 %) of diethyl 4-(3,5-di-tert-butyl-2- hydroxyphenyl)- 1 -fluoro- 1 -methyl-2-oxo-3-buten- 1 -ylphosphonate.
MS:m/e= 442: M+ 259 (56%): M+- CMeF-(PO3Et2), 184 (100%): HCMeF-(PO3Et2)+, 57: tBu + NMR: (CDC13) δ = 7.31 and 7.03 (two d, J = 2.4Hz, 2H): arom. H 6.79 (two d, J = 9.7Hz, 1H): Ph-CH=CH 6.00 (d, J = 9.7Hz, 1H): Ph-CH=CH 6.50 (broad s, 1H): phenol OH
4.42-4.25 (m, 4H): P-O- CH2-CH3
1.63(dd, J= 24.6Hz and 13.8 Hz, 3H): -CF(CH3) -P
1.46 and 1.30(two s, 9H each): t-C4H9
1.33 ( two overlapped t, J = 7Hz, 6H) : P-O- CH2-CH3 Example 13: Diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-2-oxo-3-buten-l-yl phosphonate
A mixture of 3, 5-di-tert-butyl-2 -methoxybenzaldehyde (5g, 20.16 mmol), ethyl hydrogen malonate (7.45 g, 56.45 mmol), pyridine (7.52 ml, 93 mmol) and piperidine (0.39 ml, 4.03 mmol) was heated at 110°C for 12 h. Pyridine was removed by vacuum distillation then to the residue were added a few drops of 10% HC1 to bring the pH to ca 5. The neutralised mixture was extracted with chloroform (three 50 ml portions), the separated organic phase was added to 100 ml of a sodium hydroxide solution (pH = 10) and the resulting mixture was heated for 15 min. The chloroform phase was separated, the aqueous phase further extracted with fresh chloroform, the combined chloroform phases were dried, evaporated to dryness. The residue was purified by column chromatography (SiO2, dichloromethane (DCM)) to give 4.0 g (12.5 mmol, 62%) of ethyl 3,5-di-tert-butyl-2-methoxycinnamate.
Under nitrogen atmosphere diethyl methylphosphonate (3.04 g, 19.97 mmol) was added at -78° to a solution of n-butyllithium (12.5 ml of a 1.6 M solution in hexane, 19.97 mmol) in 70 ml anhydrous THF. The reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion. The mixture was again cooled to -78° and a solution of ethyl 3,5-di-tert-butyl-2-methoxycinnamate (2.54 g, 7.99 mmol) in 20 ml dry THF was added. The resulting orange-colored mixture was left to stir at room temperature (25°C) for 2 h. Hydrolysis was carried out by adding 10 ml of a 10% HC1 solution and the product was extracted into ether, dried over MgSO4 and evaporated. The residue was purified by column choromatography (SiO2, 98/2 DCM/MeOH) to yield a yellow viscous oil (1.2 g, 2.83 mmol, 59% yield) of diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-2-oxo-3-buten-l-yl phosphonate. MS (m/e): 424: M+ 393 (100%): M+ -OMe, 367: M+ -tBu, 57 (100%): tBu NMR (CDCI3) δ = 7.94 (d, J = 16 Hz, 1H): Ph-CH=CH 7.43 (s, 1H): arom. H
6.87 (d, J = 16Hz, 1H): Ph-CH=CH 4.23-4.13 (m, 4H): P-O-CH2-CH
3.80: OCH3
3.37 (d, J = 23 Hz, 2H): CH2-P 1.41 and 1.32 (2s, 9H each): t-C4H9 1.34 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 14: Dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-dimethyl-2-oxo-3-buten- 1-yl-phosphonate
Methyl iodide (2.7 ml, 6.1 g, 43 mmol) was added dropwise to a mixture of 3,5-di-tert- butyl-2-hydroxybenzaldehyde (5.0 g, 21.3 mol), potassium carbonate (4.4 g, 32 mmol), tetra-n- butylammonium bromide (0.69 g, 2.1 mmol) dissolved in 100 ml of 2-butanone and the resulting mixture was refluxed for 3 h. Further portions of methyl iodide were added (4 X 3 ml) at regular intervals and refluxing was resumed to complete the conversion. The cooled mixture was filtered, the filtrate was concentrated under vacuum and partitioned between dichloromethane and water. Evaporation of the dried organic phase gave 5.3 g (22.4 mmol, 101% crude) of 3,5-di-tert-butyl-2- methoxybenzaldehyde. To 30 ml dry THF kept at 0°C were added sequentially TiC_4 (1.1 ml, 9.78 mmol), 3,5- di-tert-butyl-2-methoxybenzaldehyde (1.0 g, 4.03 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (0.94 g, 4.84 mmol), N-methyl morpholine (1.96 g, 19.4 mmol) then the reaction mixture was stirred for 4h at room temperature. Work up as previously described and purification by flash column chromatography (SiO2, 95/5 AcOEt/hexane) gave 0.3 g (0.71 mmol, 18 % yield) of the title compound.
MS: m/e = 424: M+, 393 (100%): 1" - OMe, 273: M+- CMe2(PO3Me2), 57: tBu+ NMR: (CDC1 ) δ = 7.97 (d, J = 15.7Hz, 1H): Ph-CH=CH 7.45 and 7.41 (2d, 2H): arom. H 7.38 (d, J = 15.5Hz, 1H): Ph-CH=CH
3.80 (d, J = 11 Hz, 6H): P-O-CH3
3.77 (s, 3H): O-Me
1.53 (d, J = 16.5Hz, 6H): -C(CH.3)2-P
1.41 and 1.33 (2s, 9H each): t-C4H9
Example 15: Diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate
The method described for the preceding example SR- 163106 was followed, using the reactants in the following amounts: THF (15 ml), TiC-4 (0.8 ml, 7.26 mmol), 3,5-di-tert-butyl-2- methoxybenzaldehyde (0.75 g, 3.03 mmol), diethyl l,l-dimethyl-2-oxopropyl phosphonate (0.8 g, 3.63 mmol), N-methyl morpholine (1.6 ml, 14.5 mmol). An amount of 0.8 g (1.77 mmol, 58 % yield) of the title compound was obtained.
MS: m/e = 452: M+, 451 (100%): M+ - OMe, 273: M+- CMe2(PO3Et2), 57: tBu+ NMR: (CDCI3) δ = 7.97 (d, J = 15.7Hz, 1H): Ph-CH=CH 7.45 and 7.40 (2d, 2H): arom. H 7.44 (d, J = 15.7 Hz, 1H): Ph-CH=CH 4.19-4.11 (m, 4H): P-O-CH2-CH3 3.76 (s, 3H): O-Me
1.52 (d, J = 16.5Hz, 6H): -C(CH3)2-P
1.40 and 1.33 (2s, 9H each): .-C4H9
1.33 (t, 7Hz, 6H): P-O-CH2-CH3
Example 16: Diisopropyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-dimethyl-2-oxo-3- buten-1-yl-phosphonate
The method described for the preceding example SR- 163106 was followed, using the reactants in the following amounts: THF (15 ml), TiC.4 (0.8 ml, 7.26 mmol), 3,5-di-tert-butyl-2- methoxybenzaldehyde (0.75 g, 3.03 mmol), diisopropyl l,l-dimethyl-2-oxopropyl phosphonate (0.9 g, 3.63 mmol), N-methyl morpholine (1.6 ml, 14.5 mmol). An amount of 1.08 g (2.08 mmol, 68 % yield) of the title compound was obtained.
MS: m/e = 480: M+, 449 (86%): M+ - OMe, 273: M+- CMe2(PO3iPr2), 57: tBu+ NMR: (CDCI3) δ = 7.95 (d, J = 15.7Hz, 1H): Ph-CH=CH
7.45 and 7.40 (2d, J= 2.4Hz, 2H): arom. H 7.44 (d, J = 15.7Hz, 1H): Ph-CH=CH
4.74 (m, 2H): P-O-CH-(CH3)2
3.76 (s, 3H): O-Me
1.49 (d, J = 16.5Hz, 6H): -C(CH3)2-P
1.40 and 1.33 (2s, 9H each): .-C4II9 1.33 and 1.32 (2d, 6Hz, 6H each): P-O-CH-(CH3)2
1.33 and 1.32 (2d, 7Hz, 6H each): P-O-CH-(CH3)2
Example 17: Diethyl 2-(3,5-di-tert-butyl-2~methoxyphenyl)-l-methyl-2-oxo- ethylphosphonate
A solution of 5.74 g (36.3 mmol) potassium permanganate in 115 ml water was added to a mixture of 6.44 g (25.9 mmol) in 160 ml water heated to 75°C. Heating was continued for a further hour then the reaction mixture was basified with 10% sodium hydroxide, filtered hot over a Buchner funnel and rinsed with hot water. The combined filtrates were cooled and acidified with 10% HC1. A fine precipitate was formed which was extracted into chloroform. The dried organic phase was evaporated to give 3.8 g (55%) of a colorless solid.
A 80 ml methanol solution containing 4.0 g (15.1 mmol) of the 3,5-di-tert-butyl-2- methoxybenzoic acid thus formed and 8 ml concentrated sulfuric acid was heated to reflux for 5h. The cooled solution was neutralized with a saturated sodium bicarbonate solution, methanol
was evaporated then the residue was basified to pH 10 with 10% sodium hydroxide. The aqueous emulsion was extracted with chloroform, the organic phase was washed with sodium bicarbonate, dried and evaporated to yield 3.89 g (14.0 mmol, 93%) of methyl 3,5 di-tert-butyl- 2-methoxybenzoate as a light brown oil. n-Butyllithium (9.3 ml of a 1.6 M solution in hexane, 14.9 mmol) was added to 20 ml of
THF cooled to -78°C, followed by diethyl ethylphosphonate (2.15 g, 12.9 mmol). The resulting solution was stirred for 15 min at -78°C, then a solution of methyl 3,5-di-tert-butyl-2- methoxybenzoate (1.8 g, 6.47 mmol) in 5 ml THF was added and the resulting reaction was left to reach room temperature over 2 h. A saturated NH4C1 solution was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of diethyl ether. The THF and ether portions were pooled, extracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 2/8 AcOEt/hexane) to give 2.36 g (5.72 mmol, 88 %) of the title compound as a yellow oil.
Example 18: Diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-dimethyl-2-oxo- ethylphosphonate
A solution of diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-methyl-2-oxo- ethylphosphonate (2.36 g, 5.92 mmol) dissolved in 7 ml THF was added to a suspension of sodium hydride (0.47 g of a 60% dispersion in mineral oil, 11.8 mmol) in 20 ml THF kept at 0°C, the reaction was left to stir for 15 min then methyl iodide (0.74 ml, 11.9 mmol) was added and the reaction mixture was left to stir at room temperature for 2h. Water was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of dichloromethane. The THF and DCM portions were pooled, extracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 95/5 DCM/MeOH) to give 1.03 g (2.41 mmol, 41 %) of the title compound.
MS: m/e= 426: M+ , 247 (62%): M+-C(CH3)2-PO3Et2, 57 (100%): tBu+
NMR: (CDCI3) δ = 7.34 and 7.13 (2d, 1H each): arom. H 4.21-4.15 (m, 4H): P-O-CH2-CH3
3.66 (Is, 3H): arom. O-CH3
1.49 (d, J = 16.5 Hz, 6H): -C(CH3)2-P 1.38 and 1.30 (2s, 9H each): t-C4H9 1.34 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 19: Dimethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-fluoro-l-methyl-2-oxo- ethylphosphonate
A solution of dimethyl 2-(3,5-di-tert-buty-2-methoxylphenyl)-l-methyl-2-oxo- ethylphosphonate (0.5 g, 1.3 mmol) dissolved in 5 ml THF was added to a suspension of sodium hydride (0.06 g of a 60% dispersion in mineral oil, 1.56 mmol) in 10 ml THF kept at 0°C, the reaction was left to stir for 15 min then l-(chloromethyl)-4-fluoro-l,4-diazoniabicyclo [2.2.2] octane bis(tetrafluoroborate) (0.5 g, 1.5 mmol) was added and the reaction mixture was left to stir at room temperature for 2 h. Water was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of DCM. The THF and DCM portions were pooled, extracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 98/2 CHCl3/MeOH) to give 0.12 g (0.3 mmol, 22%) of the title compound.
MS: 402: M+, 247 (100%): M+ - C(F)(Me)PO3Me2 NMR: (CDC13) δ = 7.47 (d, 1H) and 7.45 (t, 1H): arom. H
3.90 and 3.83 (2 d,J = 10.7 Hz, 6H): P-O-CH3
3.72 (s, 3H): arom. O-CH3
1.98 (dd, J = 24.1 and 15.3 Hz, 3H): -CF(CH3)-P
1.41 and 1.32 2(s, 9H each): t-C H9
Example 20: Dimethyl 4-(3,5-di-tert-butylphenyl)-2-oxo-3-buten-l-yl phosphonate
A mixture of 3,5-di-tert-butylbenzaldehyde (5g, 22.94 mmol), ethyl hydrogen malonate (8.48 g, 64.22 mmol), pyridine (8.64 ml, 105 mmol) and piperidine (0.45 ml, 4.59 mmol) was heated at 110°C for 12 h. Pyridine was removed by vacuum distillation then to the residue were added a few drops of 10% HCl to bring the pH to ca 5. The neutralised mixture was extracted with chloroform (three 50 ml portions), the separated organic phase was added to 100 ml of a sodium hydroxide solution (pH = 9) and the resulting mixture was heated for 15 min. The chloroform phase was separated, the aqueous phase further extracted with fresh chloroform, the combined chloroform phases were dried, evaporated to dryness. The residue was purified by column chromatography (SiO2, AcOEt/MeOH 9/1) to give 4.7 g (16.3 mmol, 71%) of ethyl 3,5- di-tert-butylcinnamate.
Under nitrogen atmosphere dimethyl methylphosphonate (2.37 g, 19 mmol) was added at -78°C to a solution of n-butyllithium (12 ml of a 1.6 M solution in hexane, 19.2 mmol) in 50 ml anhydrous THF. The reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion (slight turbidity). A solution of ethyl 3,5-di-tert-butylcinnamate (2.2 g, 7.64 mmol) in 5 ml dry THF was added. The resulting mixture was left to stir at room temperature (25°C) for 4 h. Hydrolysis was carried out by adding 10 ml of a 10% HCl solution and the product was extracted into chloroform. After drying over MgSO4, chloroform was evaporated and the residue was purified by column chromatography (SiO2, AcOEt/hexane 8/2) to give 2 g (5.45 mmol, 72%) of the title compound. MS (m/e): 366 M+, 351 : M+-Me, 309: M+ - tBu, 256: M+-HPO3Me2, 57: tBu+
NMR (CDCI3) δ = 7.67 (d, J = 16Hz, 1H): Ph-CH=CH
7.51 (t, 1H) and 7.42 (d, 2H): arom. H 6.86 (d, J = 16 Hz, 1H): Ph-CH=CH 3.82 (d, J = 11Hz, 6H): P-O-CH3
3.37 (d, J = 22Hz, 2H: CH2-P
1.35 (s, 18H): .-C4H9
Example 21: Diethyl 4-(3,5-di-tert-butylphenyl)-2-oxo-3-buten-l-yl phosphonate
Under nitrogen atmosphere diethyl methylphosphonate (3.3 g, 21.7 mmol) was added at - 78° to a solution of n-butyllithium (13.6 ml of a 1.6 M solution in hexane, 21.7 mmol) in 75 ml anhydrous THF. The reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion. The mixture was again cooled to -60° and a solution of ethyl 3,5- di-tert-butylcinnamate (2.5 g, 8.68 mmol) in 20 ml dry THF was added. The resulting orange- colored mixture was left to stir at room temperature (25°C) for 2 h. Hydrolysis was carried out by adding 10 ml of a 10% HCl solution and the product was extracted into ether. After drying over MgSO4, ether was evaporated to yield a yellow solid (2.8 g, 7.1 mmol, 81 % yield) of diethyl 4-(3,5-di-tert-butylphenyl)-2-oxo-3-buten-l-yl phosphonate. Mp=90-91°C MS (m e): 394: M+, 379: M+ -Me, 337: M+ -tBu, 256: M+-HPO3Et2, 57 (100%): tBu
NMR (CDC13) δ = 7.67 (d, J = 16 Hz, 1H): Ph-CH=CH 7.50 (t, 1H) and 7.42 (d, 2H): arom. H 6.88 (d, J = 16Hz, 1H): Ph-CH=CH 4.22-4.11 (m, 4H): P-O-CH2-CH3
3.36 (d, J = 23 Hz, 2H): CH2-P
1.35 (s, 18H): t-C4H9
1.35 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 22: Dimethyl 4-(3,5-di-tert-butylphenyl)-l,l-dimethyI-2-oxo-3-buten-l-yl- phosphonate
To 50 ml dry THF kept at 0°C were added sequentially TiCl4 (3.6 ml, 32.5 mmol), 3,5- di-tert-butylbenzaldehyde (1.0 g, 4.6 mmol), dimethyl l,l-dimethyl-2-oxopropylphosphonate (1.2 g, 5.95 mmol), N-methyl morpholine (1.85 g, 18.5 mmol) then the reaction mixture was stirred for 1 h at room temperature. Work up was carried out by adding 100 ml of iced-water, extracting the resulting mixture with three portions of 100 ml diethyl ether, washing the ether phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave an oil that was purified by flash column chromatography (SiO2, 1/1 AcOEt/hexane). An amount of 1.0 g (2.53 mmol, 56 % yield) of the title compound was obtained, mp = 50-52°C.
MS: m/e = 395: M+ + 1, 243 (100%): M+- CMe2(PO3Me2), 57: tBu+ NMR: (CDCI3) δ = 7.77 (d, J = 15.6Hz, 1H): Ph-CH=CH 7.53 (t, 1H) and 7.48 (d, 2H): arom. H 7.42 (d, J = 15.6Hz, 1H): Ph-CH=CH 3.84 and 3.78 (2d, J = 11 Hz, 6H): P-O-CH3
1.57 (d, J = 16.7Hz, 6H): -C(CH3)2-P
1.39 (s, 18H): t-C4S9
Example 23: Diethyl 4-(3,5-di-tert-butylphenyl)-l,l-dimethyI-2-oxo-3-buten-l-yl- phosphonate t-Bu
O t-Bu POsEt2
Me Me
The method described for the preceding example was followed, using the reactants in the following amounts: THF (10 ml), ΗCI4 (0.8 g, 4.14 mmol), 3,5-di-tert-butylbenzaldehyde (0.3 g, 1.38 mmol), diethyl l,l-dimethyl-2-oxopropyl phosphonate (0.4 g, 1.8 mmol), N-methyl moφholine (0.56 g, 5.52 mmol). An amoxmt of 0.52 g (1.23 mmol, 89 % yield) of the title compound was obtained.
MS: m/e = 423: M* + 1, 243 (100%): M+- CMe2(PO3Et2), 57: tBu+ NMR: (CDCI3) δ = 7.75 (d, J = 16Hz, 1H): Ph-CH=CH 7.53 (t, 1H) and 7.48 (d, 2H): arom. H 7.45 (d, J = 16Hz, 1H): Ph-CH=CH 4.19 (m, 4H): P-O-CH2-CH3
1.56 (d, J = 17Hz, 6H): -C(CH3)2-P 1.39 (s, 18H): t-C H9
1.37 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 24: Dimethyl 4-(3,5-di~tert-butylphenyl)-l,l-diethyl-2-oxo-3-buten-l-yl- phosphonate
MS: m/e = 423: M++ 1, 243 (100%): M+- C(Et)2(PO3Me2), 57 : tBu+ NMR: (CDCI3) δ = 7.72 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.49 (t, 1H) and 7.43 (d, 2H): arom. H 7.37 (d, J = 15.5Hz, 1H): Ph-CH=CH 3.79 (d, J = 11 Hz, 6H): P-O-CH3 2.08 (m, 4H): -C(CH2-CH )2-P
1.36 (s, 18H): t-C4H9
0.98 (t, J = 7 Hz, 6H): -C(CH2-CH3)2-P
Example 25: Dimethyl 4-(3,5-di-tert-butylphenyl)-l,l-cyclopentyliden-2-oxo-3-buten-l-yI- phosphonate
MS: m/e = 420: M+ 243 (100%): M+- (c-C5H8)(PO3Me2), 57: tBu+ NMR: (CDCI3) δ = 7.73 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.49 (t, 1H) and 7.43 (d, 2H): arom. H
7.30 (d, J = 15.5Hz, 1H): Ph-CH=CH 3.79 (d, J = 11 Hz, 6H): P-O-CH3
2.47, 2.20, 1.74 and 1.55 (4m, 2H each): -(c-C5H8)-P 1.35 (s, 18H): t-C4H9
Example 26: Dimethyl 2-(3,5-di-tert-butylphenyl)-l~methyl-2-oxo-ethylphosphonate
n-Butyllithium (11.5 ml of a 1.6 M solution in hexane, 18.4 mmol) was added to 40 ml of THF cooled to -78°C, followed by dimethyl ethylphosphonate (3.94 g, 28.5 mmol). The resulting solution was stirred for 15 min at -78°C, then a solution of ethyl 3,5-di-tert- butylbenzoate (2.5 g, 9.6 mmol) in 10 ml THF was added and the resulting reaction was left to gradually reach room temperature overnight. A saturated ammonium chloride solution was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of ethyl ether. The THF and ether portions were pooled, extracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 6/4 AcOEthexane) to give 2.36 g (6.67 mmol, 69 %) of the title compound.
MS: m/e= 354: M+, 217 (100%): M+- CH(CH3)-PO3Me2, 57: tBu
NMR: (CDC13) δ - 7.86 (d, 2H) and 7.67 (t, 1H): arom. H 4.23 and 4.19 (2 quartets, J=22.3 Hz, 1H): -CH(CH3)-P
3.78 and 3.74 (2d, J = 11 Hz, 6H): P-O-CH3
1.56 (dd, J = 18.3 and 7 Hz, 3H): -CH(CH3)-P
1.37 (s, 18H): t-C4S9
Example 27: Diethyl 2-(3,5-di-tert-butylphenyl)-l-methyl-2-oxo-ethylphosphonate
n-Butyllithiurn (11.5 ml of a 1.6 M solution in hexane, 18.4 mmol) was added to 40 ml of
THF cooled to -78°C, followed by diethyl ethylphosphonate (4.75 g, 28.6 mmol). The resulting solution was stirred for 15 min at-78°C, then a solution of ethyl 3,5-di-tert-butylbenzoate (2.5 g, 9.6 mmol) in 10 ml THF was added and the resulting reaction was left to gradually reach room temperature overnight. A saturated ammonium chloride solution was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of diethyl ether. The
THF and ether portions were pooled, extracted with brine, dried over MgSO4 and evaporated.
The residue was purified by column chromatography (SiO2, 4/6 AcOEt/hexane) to give 2.32 g (6.0 mmol, 63 %) of the title compound.
MS: m/e= 382: M+, 217 (100%): M+-CH(CH3)-PO3Et2, 57: tBu
NMR: (CDC13) δ = 7.85 (d, 2H) and 7.65 (t, 1H): arom. H 4.20-4.05 (m, 4H): P-O-CH2-CH3
4.20 (overlapped m, 1H): -CH(CH3)-P
1.54 (dd, J = 18.1 and 7 Hz, 3H): -CH(CH )-P
1.36 (s5 18H): t-C4H9 1.30 and 1.20 (2t, J = 7Hz, 6H): P-O-CH2-CH3
Example 28: Dimethyl 2-(3,5-di-tert-butylphenyl)-l,l-dimethyl-2-oxo-ethylphosphonate
A solution of dimethyl 2-(3,5-di-tert-butylphenyl)-l-methyl-2-oxo-ethylphosphonate (1.0 g, 2.82 mmol) dissolved in 10ml THF was added to a suspension of sodium hydride (0.23 g of a 60% dispersion in mineral oil, 5.6 mmol) in 20 ml THF kept at 0°C, the reaction was left to stir for 15 min then methyl iodide (1.2 g, 8.5 mmol) was added and the reaction mixture was left to stir at room temperature for 2h. Water was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of dichloromethane. The THF and DCM portions were pooled, extracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 4/6 AcOEt/hexane) to give 0.6 g (1.94 mmol, 68 %) of the title compound.
MS: m/e= 368: M+, 217 (100%): M+- CH(CH3)-PO3Me2, 57: tBu+
NMR: (CDCI3) δ = 7.86 (s, 2H) and 7.55 (t, 1H): arom. H 3.80 (d, J = 11 Hz, 6H): P-O-CH3 1.60 (d, J - 16.5 Hz, 6H): -C(CH ) -P 1.36 (s, 18H): t-C4Ji9
Example 29: Diethyl 2-(3,5-di-tert-butylphenyl)-l,l-dimethyl-2-oxo-ethylphosphonate
A solution of diethyl 2-(3,5-di-tert-butylphenyl)-l-methyl-2-oxo-ethylphosphonate (1.0 g, 2.62 mmol) dissolved in 10ml THF was added to a suspension of sodium hydride (0.26 g of a 60% dispersion in mineral oil, 6.53 mmol) in 15 ml THF kept at 0°C, the reaction was left to stir for 15 min then methyl iodide (1.48 g, 10.5 mmol) was added and the reaction mixture was left to stir at room temperature for 2h. Water was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of dichloromethane. The THF and DCM portions were pooled, extracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 2/3 AcOEt/hexane) to give 0.65 g (1.7 mmol, 65 %) of the title compound.
MS: m/e= 396: M+ 217 (100%): M+- C (CH3) 2 -PO3Et2, 57: tBu+
NMR: (CDCI3) δ = 7.85 (d, 2H) and 7.54 (t, 1H): arom. H 4.20-4.10 (m, 4H): P-O-CH2 -CH3
1.58 (d, J = 16.5 Hz, 6H): -C(CH3)2-P
1.35 (s, 18H): t-C4H9
1.30 (t, J=7 Hz, 6H): P-O-CH2 -CH3
Example 30: Diethyl 2-(3,4,5-trimethoxyphenyl)-l,l-dimethyl-2-oxo-ethylphosphonate
The procedure described in the preceding example was followed, using ethyl 3,4,5- trimethoxybenzoate as the starting compound. MS: m/e= 374: M+ , 195 (100%): M+-C(CH3)2-PO3Et2 NMR: (CDCI3) δ - 7.54 (s, 2H): arom. H
4.15 (m, 4H): P-O-CH2-CH3
3.91(s, 9H): arom. O-CH3
1.58 (d, J = 16.5 Hz, 6H): -C(CH3)2-P
1.31 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 31: Dimethyl 2-(3,5-di-tert-butylphenyl)-l-fluoro-l-methyl-2-oxo- ethylphosphonate
A solution of dimethyl 2-(3,5-di-tert-butylphenyl)-l-methyl-2-oxo-ethylphosphonate (1.0 g, 2.82 mmol) dissolved in 10 ml THF was added to a suspension of sodium hydride (0.175 g of a 60% dispersion in mineral oil, 4.35 mmol) in 20 ml THF kept at 0°C, the reaction was left to stir for 15 min then l-(chloromethyl)-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (1.3 g, 3.7 mmol) was added and the reaction mixture was left to stir at room temperature for 1 h. Water was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of DCM. The THF and DCM portions were pooled, extracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 2/3 AcOEt/hexane) to give 0.57 g (1.54 mmol, 59%) of the title compound.
MS: m e= 372: M+, 217 (100%): M+- CF(CH3)-PO3Me2, 57: tBu
NMR: (CDCI3) δ = 7.95 (d, J = 1.6 Hz, 2H) and 7.67 (t, 1H ): arom. H 3.92 and 3.90 (2 d,J = 10.7 Hz, 6H): P-O-CH3
1.95 (dd, J = 24.1 and 15.3 Hz, 3H): -CF(CH3)-P
1.46 (s, 18H): t-C4H9
Example 32: Diethyl 2-(3,5-di-tert-butylphenyl)-l-fluoro-l-methyl-2-oxo-ethyIphosphonate t -Bu
t-Bu Me p
A solution of diethyl 2-(3,5-di-tert-butylphenyl)-l-methyl-2-oxo-ethylphosphonate (1.0 g, 2.61 mmol) dissolved in 5 ml THF was added to a suspension of sodium hydride (0.21 g of a
60% dispersion in mineral oil, 5.23 mmol) in 15 ml THF kept at 0°C, the reaction was left to stir for 15 min then l-(chloromethyl)-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (1.85 g, 5.23 mmol) was added and the reaction mixture was left to stir at room temperature for 2 h. Water was added, the separated THF phase was collected and the aqueous phase was extracted with 3 portions of DCM. The THF and DCM portions were pooled, extracted with brine, dried over MgS04 and evaporated. The residue was purified by column chromatography (SiO2, 2/3 AcOEt/hexane) to give 0.50 g (1.25 mmol, 48%) of the title compound.
MS: m e=400: M+, 217 (100%): M+- CF (CH3)-PO3Et2, 57: tBu+ NMR: (CDC13) δ = 7.95 (t, J = 1.6 Hz, 2H) and 7.67 (t, 1H ): arom. H 4.32-4.20 (m, 4H): P-O-CH2-CH3 1.95 (dd, J = 24.1 and 15.3 Hz, 3H): -CF(CH3)-P
1.36 (s, 18H): t-C4H9 1.36 and 1.35 (two t, 6H): P-O-CH2-CH3
Example 33: Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl )-2-oxo-3- buten-1-yl phosphonate
A mixture of 3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaththaldehyde (5.09 g, 21.6 mmol), ethyl hydrogen malonate (8 g, 60.5 mmol), pyridine (8 ml, 99 mmol) and piperidine (0.43 ml, 4.3 mmol) was heated at 110°C for 7 h. To the cooled mixture were added water (50 ml) and a few drops of 10% HCl to bring the pH to ca 5 then the mixture was extracted with chloroform (threee 150 ml portions). The separated organic phase was added to 100 ml of a sodium hydroxide solution (pH = 9) and the resulting mixture was heated for 30 min. The chloroform phase was separated, the aqueous phase further extracted with fresh chloroform, the combined chloroform phases were dried, evaporated to dryness. The residue was purified by trituration in 40-60 petroleum ether to give 4 g (9.9 mmol, 46 %) of ethyl 3-[3-tert-butyl-4- hydroxy-5,6,7,8-tetrahydronaphthyl]-acrylate. Under nitrogen atmosphere dimethyl methylphosphonate (1.8 ml, 16.6 mmol) was added at -78°C to a solution of n-butylhthium (16 ml of a 1.6 M solution in hexane, 40 mmol) in 25 ml
anhydrous THF. The reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion (slight turbidity). A solution of ethyl 3-[3-tert-butyl-4-hydroxy- 5,6,7,8-tetrahydronaphthyl]-acrylate (2.5 g, 8.3 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir at room temperature (25 °C) for 3 h. Hydrolysis was carried out by adding 10 ml of a saturated NH4C1 solution and the product was extracted into chloroform. After drying over MgSO4, chloroform was evaporated and the residue was purified by column chromatography (SiO2, AcOEt/hexane 7/3) to give 0.89 g (2.34 mmol, 23%) of the title compound.
MS: m/e = 380: M+, 362: M+ - H2O, 252: M1" - H2O - HPO3Me2, 57 (100%): tBu+ NMR : (CDC13) δ - 7.98 (d, J = 16Hz, 1H): Ph-CH=CH 7.48 (s, 1H): arom. H 6.68 (d, J = 16Hz, 1H): Ph-CH=CH ca 5.3 (lH): OH 3.82 (d, J = 11 Hz, 6H): P-O-CH3
3.35 (d, J = 22Hz, 2H): CH2-P
2.86 (t, 2H), 2.59 (t, 2H), 1.89-1.82 (m, 2H) and 1.83-1.77 (m, 2H): C4H8 1.44 (s, 9H): t-C4H9
Example 34: Diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl )-2-oxo-3- buten-1-yl phosphonate t-Bu
Under nitrogen atmosphere diethyl methylphosphonate (3.8 g, 25 mmol) was added at - 78°C to a solution of n-butyllithium (25 ml of a 1.6 M solution in hexane, 40 mmol) in 25 ml anhydrous THF. The reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion (slight turbidity). A solution of ethyl 3-[3-tert-butyl-4-hydroxy- 5,6,7,8-tetrahydronaρhthyl]-acrylate (2.0 g, 8.0 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir at room temperature (25°C) for 3 h. Hydrolysis was carried out by adding 10 ml of a saturated NH4C1 solution and the product was extracted into chloroform. After drying over MgSO4, chloroform was evaporated and the residue was purified by column
chromatography (SiO2, AcOEt/hexane 7/3) to give 0.77 g (2.34 mmol, 24%) of the title compound.
MS: m/e = 408: M+, 390: M+ - H2O, 252: M+ - H2O - HPO3Et2, 57 (100%): tBu+ NMR: (CDC13) δ = 7.96 (d, J = 16Hz, 1H): Ph-CH=CH 7.46 (s, 1H): arom. H 6.70 (d, J = 16Hz, 1H): Ph-CH=CH ca 5.3 (1H): OH 4.22-4.12 (m, 4H): P-O-CH2-CH3 3.32 (d, J - 22Hz, 2H): CH2-P
2.86 (t, 2H), 2.57 (t, 2H), 1.89-1.82 (m, 2H) and 1.83-1.76 (m, 2H): GtHs- 1.41 (s, 9H): t-C4H9
1.34 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 35: Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l- dimethyl-2-oxo-3-buten-l-yl-phosphonate
To 30 ml dry THF kept at 0°C were added sequentially TiCi4 (3.5 g, 18.0 mmol), 3-tert- butyl-4-hydroxy-5,6,7,8-tetrahydronaphthaldehyde (1.5 g, 6.6 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (1.6 g, 8.6 mmol), N-methyl morpholine (2.6 g, 26.4 mmol) then the reaction mixture was stirred for 45 min at room temperature. Work up was carried out by adding 50 ml of iced-water, extracting the resulting mixture with three portions of 100 ml dichloromethane, washing the organic phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave a residue that was purified by trituration in petroleum ether. An amount of 1.7 g (4.16 mmol, 63 % yield) of the title compound was obtained.
MS: m/e = 408: M+ 298: M+ - HPO3Me2, 257: M+- CMe2(PO3Me2), 57 (100%): tBu+ NMR: (CDC13) δ = 8.15 (d, J = 18Hz, 1H): Ph-CH=CH 7.50 (s, 1H): arom. H 7.18 (d, J = 18Hz, 1H): Ph-CH=CH
ca 5.3 (1H): OH
3.81 (d, J = 11 Hz, 6H): P-O-CH3
2.86, 2.59, 1.89-1.82, 1.83-1.76 and 1.48-1.38 (total 8H): C4H8-
1.52 (d, J = 11 Hz, 6H): -C(CH3)2-P
1.44 (s, 9H): t-C4H9
Example 36: Diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl- 2-oxo-3-buten-l-yl-phosphonate
To 30 ml dry THF kept at 0°C were added sequentially ΗCI4 (2 ml, 18.0 mmol), 3-tert- butyl-4-hydroxy-5,6,7,8-tetrahydronaphthaldehyde (1.5 g, 6.5 mmol), diethyl l,l-dimethyl-2- oxopropylphosphonate (1.8 g, 8.0 mmol), N-methyl morpholine (2.5 ml, 26.4 mmol) then the reaction mixture was stirred for 45 min at room temperature. Work up was carried out by adding 50 ml of iced-water, extracting the resulting mixture with three portions of 100 ml dichloromethane, washing the organic phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave a residue that was purified by column chromatography (SiO2, AcOEt/hexane 7/3). An amount of 2.21 g (4.16 mmol, 78 % yield) of the title compound was obtained.
MS: m/e = 436: M+, 257: M+ - C(Me2)PO3Et2, 57 (100%): tBu+ NMR: (CDC13) δ = 7.99 (d, J = 16Hz, 1H): Ph-CH=CH
7.50 (s, 1H): arom. H
7.22 (d, J = 16Hz, 1H): Ph-CH=CH ca 5.3 (1H): OH 4.18-4.12 (m, 4H): P-O-CH2-CH3
2.86 (t, 2H), 2.57 (t, 2H), 1.88-1.82 (m, 2H) and 1.82-1.76 (m, 2H): C4H8-
1.51 (d, J = 16.7 Hz, 6H): -C(CH3)2-P
1.43 (s, 9H): .-C4H9
1.33 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 37: Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2- oxo-3-buten-l-yl-phosphonate
To a suspension of sodium hydride (1.55 g of a 60% suspension in mineral oil, 64.66 mmol) in 60 ml THF was added a solution of 3-tert-butyl~4-hydroxy-5,6,7,8- tetrahydronaphthaldehyde (6.0 g, 25.86 mmol) in 10 ml THF and the resulting mixture was stirred for 30 min at 0°C. 2-Methoxyethoxymethyl chloride (6.44 g, 51.72 mmol) was added dropwise and the resuting mixture was stirred for 4 h at room temperature. After hydrolysis by a saturated NH4C1 solution, the reaction mixture was partitioned between water and DCM. The dried organic phase was evaporated and the residue was purified by column chromatography (SiO2, DCM) to give 4.8 g of 3-tert-butyl-4-(2-methoxyethoxymethoxy)-5,6,7,8- tetrahydronaphthaldehyde (58%).
To a suspension of sodium hydride (0.90 g of a 60% suspension in mineral oil, 37.50 mmol) in 60 ml THF was added a solution of triethyl phosphonoacetate (4.03 g, 18 mmol) in 10 ml THF and the resulting mixture was stirred for 30 min at 0°C. 3~Tert-butyl-4-(2- methoxyethoxymethoxy)-5,6,7,8-tetrahydronaphthaldehyde (4.8 g, 15 mmol) was added dropwise and the resuting mixture was stirred for 2 h at room temperature. After hydrolysis by a saturated NH4C1 solution, the reaction mixture was partitioned between water and DCM. The dried organic phase was evaporated and the residue was purified by column chromatography (SiO2, 98/2 DCM/MeOH) to give 2.71 g of ethyl 3-[3-tert-butyl-4-(2-methoxyethoxymethoxy)- 5,6,7,8-tetrahydronaphthyl] acrylate (46%). n-Butyllithium (10.86 ml of a 1.6 M solution in hexane, 17.37 mmol) was added to 80 ml of THF cooled to -78°C, followed by dimethyl ethylphosphonate (2.4 g, 17.37 mmol). The resulting solution was stirred for 15 min at -78°C, then a solution of 2.71 g (6.95 mmol) of ethyl 3-[3-tert-butyl-4-(2-methoxyethoxymethoxy)-5,6,7,8-tetrahydronaphthyl] acrylate in 10 ml THF was added and the resulting reaction was left to stir at -78°C for 1 h. A saturated NH4C1 solution was added, the separated THF phase was collected and the aqueous phase was extracted with DCM. The THF and DCM portions were pooled, reextracted with brine, dried over MgSO4 and evaporated. The residue was purified by column chromatography (SiO2, 98/2 DCM/MeOH) to give 1.6 g (3.32 mmol, 47 %) of dimethyl 4-[3-tert-butyl-4-(2-methoxyethoxymethoxy)- 5,6,7,8-tetrahydronaphthyl]-l-methyl-2-oxo-3-buten-l-yl-phosphonate .
A mixture containing the latter compound (1.6 g, 3.32 mmol) and TFA (1.89 g, 16.6 mmol) in 50 ml DCM was stirred at room temperature for 1 h. A 10% sodium hydroxide solution was added until pH = 5-6, the aqueous solution extracted with DCM, dried and evaporated to dryness. Purification by column chromatography (SiO2, 98/2 DCM/MeOH gave 0.35 g (30%)) of the title compound (mp=128-130°C after recrystallisation from DCM/Petroleum ether). MS: m/e = 394: M+, 376: M " - H20, 257: M+- CHMe (PO3Me2), 57 (79%): tBu ", 138 (100 %):
HCHMe (P03Me2) + NMR: (CDC13) δ = 7.98 (d, J = 15.6Hz, lH): Ph-CH=CH
7.49 (s, 1H): arom. H 6.79 (d, J = 15.6Hz, 1H): Ph-CH=CH ca 5.3 (lH): OH 3.81 (2d, J = 11 Hz, 6H): P-O-CH3 3.58-3.48 (2 quartets, 1H): CH(CH ) -P
2.86, 2.59, 1.89-1.83 and 1.82-1.78 (total 8H): C4H 1.49 (2d, J = 7 Hz, 3H): -CH(CH3) -P
1.43 (s; 9H): t-C4H9
Example 38: Diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2- oxo-3-buten-l-yl-phosphonate
Under nitrogen atmosphere diethyl ethylphosphonate (2.89 g, 17.38 mmol) was added at -78°C to a solution of n-butyllithium (10.9 ml of a 1.6 M solution in hexane, 17.38 mmol) in 75 ml anhydrous THF. The reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion. A solution of ethyl 3-[3-tert-butyl-4-hydroxy-5,6,7,8- tetrahydronaphthyl] -acrylate (2.1 g, 6.95 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir at -78°C for 2 h, then at 25°C for lh. Hydrolysis was carried out by adding 10 ml of a saturated NH CI solution and the product was extracted into DCM. After drying over MgSO4, DCM was evaporated and the residue was purified by column chromatography (SiO2, 98/2 DCM/MeOH) to give an oil that was further purified by
recrystallization from petroleum ether/DCM. An amount of 1.3 g (3.08 mmol, 44 %) of the title compound was obtained; mp=l 10-111°C.
MS: m/e = 422: M+, 257: M+ - CH(Me)PO3Et2, 57 (77%): tBu+ NMR: (CDC13) δ = 7.99 (d, J = 15.6Hz, 1H): Ph-CH=CH
7.49 (s, 1H): arom. H
6.82 (d, J = 15.6Hz, 1H): Ph-CH=CH ca 5.3 (1H): OH
4.18-4.12 (m, 4H): P-O-CH2-CH3 3.53-3.43 (2 quartets, J= 7Hz, 1H): CH(CH3) -P
2.86 (t, 2H), 2.57 (t, 2H), 1.88-1.82 (m, 2H) and 1.82-1.76 (m, 2H): C4H8- 1.49 and 1.45 (2d, J = 7 Hz, 3H): -CH(CH3) -P
1.43 (s, 9H): t-C4H9
1.33 (2t overlapped, J = 7Hz, 6H): P-O-CH2-CH3
Example 39: Dimethyl 4- (3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl )-2-oxo-3- buten-1-yl phosphonate
A mixture of 3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthaldehyde (4.8 g, 18 mmol), ethyl hydrogen malonate (8 g, 61 mmol), pyridine (8 ml, 99 mmol) and piperidine (0.43 ml, 4.3 mmol) was heated at 110°C for 8 h. To the cooled mixture were added water (50 ml) and a few drops of 10% HCl to bring the pH to ca 5 then the mixture was extracted with chloroform (three 150 ml portions). The separated organic phase was added to 100 ml of a sodium hydroxide solution (pH = 9) and the resulting mixture was heated for 15 min. The chloroform phase was separated, the aqueous phase further extracted with fresh chloroform, the combined chloroform phases were dried, evaoparted to dryness. The resisue was purified by column chromatography (SiO2, AcOEt/hexane 5/95) to give 4 g (12.6 mmol, 70%) of ethyl 3-[3-tert-butyl-4-methoxy- 5,6,7,8-tetrahydronaphthyl]-acrylate.
Under nitrogen atmosphere dimethyl methylphosphonate (2.5 g, 20 mmol) was added at -78°C to a solution of n-butyllithium (21 ml of a 1.6 M solution in hexane, 33 mmol) in 25 ml anhydrous THF. The reaction mixture was stirred at -70° for 30 min to allow for complete
formation of the lithium anion (slight turbidity). A solution of ethyl 3-[3-tert-butyl-4-methoxy- 5,6,7,8-tetrahydronaphthyl]-acrylate (2.0 g, 6.6 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir at room temperature (25°C) for 18 h. Hydrolysis was carried out by adding 10 ml of a 10% HCl solution and the product was extracted into chloroform. After drying over MgSO4, chloroform was evaporated and the residue was purified by column chromatography (SiO2, AcOEt/hexane 8/2) to give 0.51 g (1.29 mmol, 20%) of the title compound.
MS: m/e = 394: M+, 376: M+ - H2O, 266: M+ - H2O - HPO3Me2, 57 (100%): tBu+ NMR: (CDC13) δ = 8.01 (d, J = 16Hz, 1H): Ph-CH=CH
7.50 (s, 1H): arom. H
6.73 (d, J - 16Hz, 1H): Ph-CH=CH
3.86 (d, J = 11 Hz, 6H): P-O-CH3
3.84 (s, 3H): arom. O-CH3 3.39 (d, J = 22Hz, 2H): CH2-P
2.92 (t, 2H), 2.81 (t, 2H), 1.91-1.86 (m, 2H) and 1.80-1.76 (m, 2H): C4H8- 1.44 (s, 9H): t-C4H9
Example 40: Diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl )-2-oxo-3-buten- 1-yl phosphonate t-Bu
Under nitrogen atmosphere diethyl methylphosphonate (2.8 g, 18 mmol) was added at - 78°C to a solution of n-butyllithium (19 ml of a 1.6 M solution in hexane, 30 mmol) in 25 ml anhydrous THF. The reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion. A solution of ethyl 3-[3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthyl]-acrylate (1.9 g, 6.0 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir at room temperature (25°C) for 4 h. Hydrolysis was carried out by adding 10 ml of a 10% HCl solution and the product was extracted into chloroform. After drying over MgSO4, chloroform was evaporated and the residue was purified by column chromatography (SiO2, AcOEt/hexane 8/2) to give 0.79 g (1.87 mmol, 31%) of the title compound.
MS: m/e = 423: M+ + 1, 404: M* - H20, 266: M+ - H2O - HPO3Et2, 57 (100%): tBu+
δ = 7.96 (d, J = 16Hz, 1H): Ph-CH=CH 7.45 (s, 1H): arom. H 6.71 (d, J = 16Hz, 1H): Ph-CH=CH 4.22-4.12 (m, 4H): P-O-CH2-CH3
3.79 (s, 3H): arom. O-CH3
3.33 (d, J = 22Hz, 2H): CH2-P
2.87 (t, 2H), 2.77 (t, 2H), 1.85-1.81 (m, 2H) and 1.74-1.71 (m, 2H): C4H8- 1.39 (s, 9H): t-C4H9 1.33 (t, J = 7Hz, 6H): P-O-CH -CH3
Example 41: Dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l- dimethyl-2-oxo-3-buten-l -yl-phosphonate t-Bu
Methyl iodide (5.6 ml, 0.09 mol) was added dropwise to a mixture of 3-tert-butyl-4- hydroxy-5,6,7,8-tetrahydronaphthaldehyde (7.0 g, 0.031 mol), potassium carbonate (8 g, 0.06 mol), tetra-n-butylammonium bromide (0.8 g, 0.002 mol) dissolved in 10 ml of 2-butanone and the resulting mixture was refluxed for 3 h. The cooled mixture was filtered, the filtrate was concentrated under vacuum and partitioned between dichloromethane and water. Evaporation of the dried organic phase gave 7.3 g (0.030 mmol, 95% crude) of 3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthaldehyde.
To 30 ml dry THF kept at 0°C were added sequentially TiC_4 (1.2 ml, 10.5 mmol), 3-tert- butyl-4-methoxy-5,6,7,8-tetrahydronaphthaldehyde (1.0 g, 4.1 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (1.02 g, 5.3 mmol), N-methyl morpholine (2 ml, 16.4 mmol) then the reaction mixture was stirred for 2 h at room temperature. Work up was carried out by adding 50 ml of iced-water, extracting the resulting mixture with three portions of 100 ml dichloromethane, washing the organic phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave a residue that was purified by trituration in petroleum ether. An amoxmt of 0.52 g (1.23 mmol, 30 % yield) of the title compound was obtained. MS: m/e =422: M+, 312 (100%): Iv -HPO3Me2, 271: M+-CMe2(PO3Me2), 57: tBu+
NMR: (CDCI3) δ = 8.04 (d, J = 15.4Hz, 1H): Ph-CH=CH 7.53 (s, 1H): arom. H 7.24 (d, J = 15.4Hz, 1H): Ph-CH=CH 3.84 (d, J = 11 Hz, 6H): P-O-CH3
3.83 (s, 3H): arom. O-CH3
2.90 (t, 2H), 2.80 (t, 2H), 1.90-1.83 (m, 2H) and 1.79-1.75 (m, 2H): C4H8- 1.56 (d, J = 16.7 Hz, 6H): -C(CH3)2-P
1.46 (s, 9H): t-C4H9
Example 42: Diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl- 2-oxo-3-buten-l-yl-phosphonate
The method described for the preceding example was followed, using the reactants in the following amounts: THF (50 ml), ΗCI4 (1.2 ml, 10.5 mmol), 3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthaldehyde (1.0 g, 4.1 mmol), diethyl l,l-dimethyl-2-oxopropyl phosphonate (1.4 g, 5.3 mmol), N-methyl morpholine (2 ml, 16.4 mmol). An amount of 1.26 g (2.8 mmol, 68 % yield) of the title compound was obtained.
MS: m/e =450: M+, 312 (100%): M+ -HPO3Et2, 271: M+-CMe2(PO3Et2), 57: tBu+ NMR: (CDCI3) δ = 8.03 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.53 (s, 1H): arom. H 7.23 (d, J = 15.5Hz, 1H): Ph-CH=CH 4.22-4.16 (quintet, 4H): P-O-CH2-CH3 3.83 (s, 3H): arom. O-CH3
2.91 (t, 2H), 2.80 (t, 2H), 1.89-1.84 (m, 2H) and 1.79-1.75 (m, 2H): C4H.8- 1.55 (d, J = 16.7 Hz, 6H): -C(CH3)2-P
1.45 (s, 9H): t-C4H9
1.37 (t, J = 7Hz, 6H): P-O-CH2-CH3
Example 43: Diisopropyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l- dimethyl-2-oxo-3-buten-l-yl-phosphonate
The method described for the preceding example was followed, using the reactants in the following amounts: THF (30 ml), TiCl4 (1.4 ml, 12.2 mmol), 3-tert-butyl-4-methoxy-5 ,6,7,8- tetraliydronaphthaldehyde (1.0 g, 4.1 mmol), diisopropyl l,l-dimethyl-2-oxopropyl phosphonate (1.3 g, 5.3 mmol), N-methyl morpholine (1.8 ml, 16.3 mmol). An amount of 0.93 g (1.95 mmol, 48 % yield) of the title compound was obtained.
MS: m/e =478: M+, 312 (100%): M+ -HPO3iPr2, 271: M+-CMe2(PO3iPr2), 57: tBu+ NMR: (CDC13) δ = 7.96 (d, J = 15.5Hz, 1H): Ph-CH=CH 7.48 (s, 1H): arom. H 7.27 (d, J = 15.5Hz, 1H): Ph-CH=CH 4.74 (m, 4H): P-O-CH-(CH3)2 3.78 (s, 3H): arom. O-CH3
2.86 (t, 2H), 2.76 (t, 2H), 1.84-1.79 (m, 2H) and 1.75-1.70 (m, 2H): C4H8- 1.47 (d, J = 16.7 Hz, 6H): -C(CH3)2-P
1.41 (s, 9H): t-C H9
1.32 and 1.31 (2 d, 7Hz, 6H each): P-O-CH-(CH3)2 1.47 (s, 18H): X-C4H9
1.37 and 1.36 (2t, J = 7Hz, 6H): P-O-CH2-CH3
Example 44: Dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-diethyl- 2-oxo-3-buten-l-yl-phosphonate
The method described for the preceding example was followed, using the reactants in the following amounts: THF (20 ml), ΗCI4 (1.45 ml, 13.2 mmol), 3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthaldehyde (0.47 mmol,1.83 mmol), dimethyl l,l-diethyl-2-oxopropyl
phosphonate (0.59 g, 2.36 mmol), N-methyl morpholine (0.80 ml 7.26 mmol). An amount of 0.25 g (0.56 mmol, 30 % yield) of the title compound was obtained.
MS: m/e =450: M+, 271: M+-CEt2(PO3Me2), 57 (100%): tBu+ NMR: (CDC13) δ = 7.98 (d, J = 15.4Hz, 1H): Ph-CH=CH 7.48 (s, 1H): arom. H 7.20 (d, J = 15.4Hz, 1H): Ph-CH=CH 3.80 (d, J= 11Hz, 6H): P-O-CH3
3.79 (s, 3H): arom. O-CH3 2.88 (t, 2H), 2.78 (t, 2H), 1.85-1.80 (m, 2H) and 1.75-1.70 (m, 2H): C4H8-
2.11-2.00 (m,4H): -C(CHrCH3)2-P
1.42 (s, 9H): t-C H9
0.98 (t, J = 7.5 Hz, 6H): -C(CH2-CH3)2-P
Example 45: Dimethyl 4-(3-tert-butyI-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l- cyclopentyIiden-2-oxo-3-buten-l-yl-phosphonate t-Bu
The method described for the preceding example SR-158806 was followed, using the reactants in the following amounts: THF (20 ml), ΗCI4 (1.45 ml, 13.2 mmol), 3-tert-butyl-4- methoxy-5,6,7,8-tetiahydronaphthaldehyde (0.47 g, 1.83 mmol), dimethyl 1,1-cyclopentyliden- 2-oxopropyl phosphonate (0.59 g 2.36 mmol), N-methyl morpholine 0.80 ml, 7.26 mmol). An amoxmt of 0.31 g (0.69 mmmol, 38 % yield) of the title compound was obtained.
MS: m/e =448: M+, 271: M+-c-C5H8 (PO3Me2), 57 (100%): tBu+ NMR: (CDCI3) δ = 8.00 (d, J = 15.4Hz, 1H): Ph-CH=CH 7.48 (s, 1H): arom. H 7.12 (d, J = 15.4Hz, 1H): Ph-CH=CH 3.80 (d, J= 10.3Hz, 6H): P-O-CH3
3.79 (s, 3H): arom. O-CH3
2.88 (t, 2H), 2.78 (t, 2H), 1.85-1.78 (m, 2H) and 1.77-1.70 (m, 2H) (total 8H): C4H8-
2.50-2.44 (m,2H), 2.25-2.15 (m,2H), 1.77-1.70 (m,2H),1.60-1.55 (m,2H) ( total 8 H):-c- C5H8-P 1.41 (s, 9H): t-C H9
Example 46: Dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2- oxo-3-buten-l-yl-phosphonate
Under nitrogen atmosphere dimethyl ethylphosphonate (4.6 g, 29 mmol) was added at -
78°C to a solution of n-butyllithium (30 ml of a 1.6 M solution in hexane, 48 mmol) in 25 ml anhydrous THF. The reaction mixture was stirred at -70° for 30 min to allow for complete formation of the lithium anion. A solution of ethyl 3-[3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthyl] -acrylate (3.0 g, 9.5 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir at room temperature (25 °C) for 4 h. Hydrolysis was carried out by adding 10 ml of a saturated NH4C1 solution and the product was extracted into chloroform. After drying over MgSO4, chloroform was evaporated and the residue was purified by column chromatography (SiO2, AcOEt/hexane 8/2) to give 0.98 g (2.4 mmol, 25%) of the title compound. MS: m/e =408: M+, 271 : M+-CHMe (PO3Me2), 138 (100%): HCHMe (PO3Me2), 57: tBu+ NMR: (CDC13) δ = 7.98 (d, J = 15.6Hz, 1H): Ph-CH=CH 7.47(s, 1H): arom. H 6.81 (d, J = 15.6Hz, 1H): Ph-CH=CH 3.80 and 3.79 (2d, J= 11Hz, 6H): P-O-CH3
3.79 (s, 3H): arom. O-CH3
3.56 and 3.50 (2 quartets, J=7 Hz, 1H): CH(CH3)-P
2.87 (t, 2H), 2.76 (t, 2H), 1.85-1.80 (m, 2H) and 1.75-1.70 (m, 2H): C4H8- 1.49 (2d, J = 7 Hz, H): -CH(CH3) -P 1.40 (s, 9H): t-C4H9
Example 47: Diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2- oxo-3-buten-l-yl-phosphonate
Under nitrogen atmosphere diethyl ethylphosphonate (2.63 g, 15.8 mmol) was added at - 78°C to a solution of n-butyllithium (9.9 ml of a 1.6 M solution in hexane, 15.8 mmol) in 25 ml anhydrous THF. The reaction mixture was stirred at -78° for 30 min to allow for complete formation of the lithium anion. A solution of ethyl 3-[3-tert-butyl-4-methoxy-5,6,7,8- tetrahydronaphthyl] -acrylate (2.0 g, 6.3 mmol) in 10 ml dry THF was added. The resulting mixture was left to stir -78°C for 1 h. Hydrolysis was carried out by adding 10 ml of a saturated ammonium chloride solution and the product was extracted into dichloromethane (DCM). After drying over MgSO4, DCM was evaporated and the residue was purified by column chromatography (SiO2, DCM/MeOH 98/2) to give 2.2 g (4.3 mmol, 82 %) of the title compound.
MS: m/e =436: M+, 271: M+-CHMe(PO3Et2), 57: tBu+ NMR: (CDCI3) δ = 7.97 (d, J = 15.5Hz, 1H): Ph-CH=CH
7.48 (s, 1H): arom. H
6.84 (d, J = 15.5Hz, 1H): Ph-CH=CH 4.20-4.12 (m, 4H): P-O-CH2-CH3 3.79 (s, 3H): arom. O-CH3
3.51 and 3.46 (2 quartets, J= 7Hz, 1H): -CH(CH3)-P
2.98 (t, 2H), 2.78 (t, 2H), 1.86-1.82 (m, 2H) and 1.76-1.70 (m, 2H): C4H8-
1.49 and 1.46 (2d, J = 7 Hz, 3H): -CH(CH3)-P
1.40 (s, 9H): --C4H9 ca 1.37 (2 overlapped t, J = 7Hz, 6H): P-O-CH2-CH3
Example 48: Dimethyl 4-(3-tert-butyl-5,5-dimethyl-4-hydroxy-5,6,7,8-tetrahydro-l- naphthyl)-! ,1 -d
To 5 ml dry THF kept at 0°C were added sequentially TiCi4 (87 mg, 0.46 mmol), 5,5- dimethyl-3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthaldehyde (50 mg, 0.192 mmol), dimethyl l,l-dimethyl-2-oxopropylphosphonate (45 mg, 0.23 mmol), N-methyl morpholine (93 mg, 0.92 mmol) then the reaction mixture was stirred for 45 min at room temperature. Work up was carried out by adding iced-water, extracting the resulting mixture with dichloromethane, washing the organic phase with brine and drying over magnesium sulfate. Evaporation of the solvent gave a residue that was purified by column chromatography (SiO2, 8/2 AcOEt/Hexane). An amount of 15 mg (0.034 mmol, 18 % yield) of the title compound was obtained.
Example 49: Dimethyl 4-(3-tert-butyl-4-hydroxy-l-naphthyl)-l,l-dimethyl-2-oxo-3-buten- 1-yl-phosphonate
To 30 ml dry THF kept at 0°C were added sequentially T1CI4 (2 ml, 2.9 g, 15.5 mmol),
3-tert-butyl-4-hydroxynaphthaldehyde (1.5 g, 6.6 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (1.6 g, 7.83 mmol), N-methyl morpholine (2.5 ml, 3.12 g, 30.9 mmol) then the reaction mixture was stirred for 1 h at room temperature. Work up as previously described and purification by flash column chromatography (SiO2, 7/3 AcOEt/hexane) gave 2.21 g (5.5 mmol, 82 % yield) of the title compound.
MS: m/e = 404: M+, 253 (100%): M+- CMe2(PO3Me2), 57 : tBu+ NMR: (CDCI3) δ = 8.48 (d, J = 15 Hz, 1H): Ph-CH=CH 8.20, 8.13, 7.91, 7.53 (4m, 5H total): naphthyl H
7.39 (d, J = 15 Hz, 1H): Ph-CH=CH 6.30 (broad s, 1H): OH 3.80 (d, J = 11Hz, 6H): P-O-CH3 1.55 (d, J = 16.5 Hz, 6H): -C(CH3)2-P
1.54 (s, 9H): t-C4H9
Example 50: Dimethyl 4-(3-benzyl-4-hydroxy-l-naphthyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate
To 20 ml dry THF kept at 0°C were added sequentially ΗCI4 (1.0 g, 5.3 mmol), 3- benzyl-4-hydroxynaphthaldehyde (0.6 g, 2.2 mmol), dimethyl l,l-dimethyl-2- oxopropylphosphonate (0.54 g, 2.78 mmol), N-methyl morpholine (0.95 g, 9.3 mmol) then the reaction mixture was stirred for 1 h at room temperature. Work up as previously described and purification by flash column chromatography (SiO2, 7/3 AcOEt/hexane) gave 0.91 g (2.1 mmol,
85 % yield) of the title compound.
MS: m/e = 438: M+, 287 (100%): M+- CMe2(PO3Me2), 91 (100%) : C7H7 + NMR: (CDC13) δ = 8.50 (d, J = 15.3 Hz, 1H) :Ph-CH=CH 8.20, 8.22, 7.70, 7.55, 7.50: (5m, 5H total): naphthyl H
7.25 (m, 5H total): benzyl H 6.15 (broad s, 1H): OH 3.79 (d, J = 11Hz, 6H): P-O-CH3 1.55 (d, J = 16.5 Hz, 6H): -C(CH3)2-P
Example 51: Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-l- butyl-phosphonate
The title compound was obtained in 40% yield by reducing a solution of dimethyl 4-(3- tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l-yl-phosphonate (0.20 g) over a suspension of Pd/C (0.15 g) in ethyl acetate.
MS: m e=382: M+ 325: M+-t-Bu, 57 (100%): tBu+ NMR (CDC13) δ = 6.93 (s, 2H): arom. H
4.77 (s, 1H): OH
3.79 (d, J = 11.3Hz, 6H): P-O-CH3
3.10 (d, J = 22.6Hz, 2H): CH2-P
2.88-2.79 (2m, 2H): Ph-CH2- CH2 and Ph-CH2-CH2
2.66 (t, 2H), 2.58 (t, 2H), 1.86-1.82 (m, 2H) and 1.81-1.76 (m, 2H): C4H8- 1.41 (s, 9H): t-C4H9
Example 52: Dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l- dimethyl-2-oxo-l-butyl-phosphonate t-Bu
A solution of dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l- dimethyl-2-oxo-3 -buten- 1 -yl-phosphonate (0.50 g, 1.22 mmol) in 30 ml AcOEt was added to a suspension of Palladium over active charcoal (0.25 g) and the mixture was submitted to hydrogenation at room temperature in a Parr hydrogenation apparatus for 10 min. The reaction mixture was filtered over a pad of MgSO4, the filtrate was evaporated and the residue was purified by column chromatography (SiO2, 3/2 AcOEt/hexane). An amount of 0.4 g (1.07 mmol, 88%>) of the title compound was obtained.
MS: m/e = 410: M+, 353: M+ - t-Bu, 300: M+ - HPO3Me2, 57: tBu+
δ = 6.93 (s, 1H): arom. H 4.80 (s, 1H): OH 3.76 (d, J = 11Hz, 6H): P-O-CH3
2.91 (distorted t, J = 7 Hz, 2H): Ph-CH2-CH2 2.80 (distorted t, J = 7 Hz, 2H): Ph-CH2-CH2 2.67 (t, 2H), 2.59 (t, 2H), 1.88-1.83 (m, 2H) and 1.80-1.75 (m, 2H): Hs-
1.43 (d, J = 17Hz, 6H): -C(CH3)2-P 1.41 (s, 9H): t-C4H9
Example 53: Dimethyl 4-(5-tert-butyl-2-hydroxy-3-methoxyphenyl)-l,l-dimethyl-2-oxo-l- butyl-phosphonate
The title compound was obtained in 80% yield by reducing a solution of dimethyl 4-(5- tert-butyl-2-hydroxy-3-methoxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate (0.20 g) over a suspension of Pd/C (0.15 g) in ethyl acetate.
MS: m e = 386: M+, 233: M+- 2H - CMe2(PO3Me2), 57 : tBu+ NMR: (CDC13) δ = 6.77 and 6.75 (2d, 2H): arom. H 5.7 (s, 1H): OH
3.89 (s, 3H): arom. O-CH3
3.75 (d, J = 11 Hz, 6H): P-O-CH3
3.03 (t, J = 7 Hz, 2H): Ph-CH2-CH2 "
2.89 (t, J = 7 Hz, 2H): Ph-CH2-CH2 1.42 (d, J = 16.9Hz, 6H): -C(CH3)2-P
1.29 (s, 9H): t-C4H9
Example 54: Dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-dimethyl-2-oxo-l-butyl- phosphonate
The title compoxmd was obtained in 40% yield by reducing a solution of dimethyl 4-(3,5- di-tert-butyl-2-hydroxyphenyl)-l,l-dimethyl-2-oxo-3 -buten- 1 -yl-phosphonate (0.20 g) over a suspension of Pd/C (0.15 g) in ethyl acetate.
MS: m/e = 412: M+, 259: M+- 2H - CMe2(PO3Me2), 57: tBu+
BIOLOGICAL RESULTS
Example 55: HMG-CoA Reductase Assay
The ability of compounds of Formula (I) to affect HMG-CoA levels was investigated in the HeLa cell line obtained from the American Type Culture Collection organization (ATCC).
A. Experimental Protocol
Quantification of HMGR levels by Immunoblotting HeLa cells (ATCC) were seeded in 6 wells plates (8.105 cells per well) in DMEM contaimng 10% fetal calf serum (FCS) and grown for 1 day. Then, the medium was replaced by DMEM without FCS and the cells were further grown for 16 h. Products were tested at 1 and 10 μM final concentrations; they were added as 1000-fold concentrated stock solutions in 50% EtOH and 50% DMSO. After a 5 h incubation period, cells were washed in ice cold PBS and lysed in 200 μl/well of the following buffer: 20 mM Hepes pH 7.4, 50 mM NaCl, 10 mM EDTA, 10 mM EGTA, 2.2% DMSO, 1% Triton X-100 and the Complete Protease Inhibitor cocktail (Roche Diagnostics). Cells were kept for 15 min on ice; then, cell lysates were collected and spun at 14K rpm for 20 min. The supernatants were kept and protein concentrations were determined using the BioRad DC protein assay (BioRad). Samples were diluted in sample buffer containing 5% β-mercaptoethanol and loaded on 7.5% SDS-PAGE without prior boiling. HMG- CoA reductase levels were analysed by subsequent immunoblotting using mouse A9 mAbs (hybridoma cells CRL-1811; ATCC). Bound A9 antibodies were revealed by goat anti-mouse IgG peroxidase-coupled antibodies (Sigma) and SuperSignal West Dura Extended Duration Substrate (Pierce) followed by autoradiography.
B. Results
Compounds (I) were tested at two different concentrations: 1 and 10 μM. The relative potencies of Compounds (I) for decreasing HMG-CoA reductase were expressed as approximative % change of samples treated with 10 μM test compoxxnds of Formula (I) over control samples. HMG-CoA reductase levels were estimated by comparing samples from treated cells with samples from non-treated cells. Estimation of the effect of the compounds was established as follows:
++++ is 100% decrease in HMGR levels at 10 and at 1 μM +++ is 100% decrease in HMGR levels at 10 μM /50-99% at 1 μM ++ is 50-99% decrease in HMGR levels at 10 μM / 0-50% at 1 μM + is 10-49% decrease in HMGR levels at 10 μM / 0% at 1 μM (+) is 1-10% decrease in HMGR levels at 10 μM / 0% at 1 μM.
The results are summarized in TABLE 1.
TABLE 1 - Reduction in the amount of HMG-CoA reductase by Compounds of Formula (I) wherein Y is O if z1
Ar - ,/ (I)
Example 56: In Vivo Murine Bone Anabolic Activity Model
The bone anabolic activity of selected compoxxnds of Formula (I) displaying potent HMG-CoA reducing activity was investigated in mice. This species has been used extensively to study the genetic, physiologic and pharmacologic regulation of bone metabolism and has been shown to be a relevant model.
A. Experimental Protocol Male OF1 mice (Charles River, France), weighing ca 30g were divided into groups of 6 animals. Animals were maintained on a 12 h- 12 h light cycle and were fed ad libitum with UAR
A03 (France) chow. The calcium and phosphorus contents of the food were respectively 0.8% and 0.6%). Food consumption and body weight were measured on a weekly basis.
Control group received standard chow and Treated groups received test compounds mixed with the diet, at the required concentration to the targeted dose level. Doses used varied from 12.5 mg/kg to 100 mg/kg. Active compounds showed activity around the minimal dose 12.5 mg/kg.
At the end of the treatment period (4 weeks) animals were sacrificed, blood was collected, serum was obtained and femurs and vertebra were dissected and frozen. Bone mineral content measurements were performed employing a bone scanner (XCT research series, Stratec, Germany). Measurements were made in the trabecular-rich distal metaphyseal region of the femurs or in the proximal head of the lumbar vertebras and the following bone parameters were measured: trabecular and cortical density in femurs and trabecular density in vertebrs. The analysis parameters were: peelmode 4, threshold 280 mg/cm3, inner threshold 500 mg/cm3 and peel 5%. Briefly the XCT Bone Scanner is a fully automated measuring system based on the
Peripheral Quantitative Computer Tomography (pQCT) technique for the determination of bone density. The pQCT technique is a highly sensitive method that allows the monitoring of bone loss and bone gain over time in a non-invasive manner. It has been validated for measuring bone parameters in mice treated with bone anabolic agents such as the hormone PTH and the antiresorptive bisphosphonic acids (see Feretti et al, 1996 and Gasser, 1995). It has been shown previously that the pQTC technique employed correlates with bone dry weight. For instance, results published by Rosenberg et al (Osteoporosis International, 5, 47-53 (1995)) indicate that bone dry weight, after complete mineralisation at 800°C, was highly correlated with bone mineral content (BMC) as measured by pQCT.
B. Results
Table 2 shows that two representative compounds of Formula (I) markedly increase bone formation: at 12.5mg/kg, Compounds 52 and 37 increased vertebra trabercular density by respectively 11 and 26 %; furthermore at 50 mg/kg Compound 37 increased the vertebra density by 57 %. The compounds of the present invention are thus useful in pharmaceutical formulations for the prevention and treatment of diseases where bone growth is necessary.
Table 2 - In Vivo effect of Compounds of Formula (I), wherein Y is O, on Mouse Bone
Y 1
II / z
Ar L — P. ( i) X z'
Example 57: Tablet Formation
A tablet composition containing a compound of formula (I) is prepared by mixing and compressing in a tablet making machine the flowing ingredients: 200 mg compound of formula (I); 200 mg lactose; and 20 mg magnesium stearate.
REFERENCES
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
Berge et al, "Pharmaceutical salts," J. Pharm. Sci., 66:1-19, 1977.
Garnero et al., "Markers of bone turnover for the management of patients with bone metastasis from prostate cancer," Br. J. Cancer, 82:858-64, 2000. Ferretti et al, Bone 18 (2): 97-102 (1996) Gasser, Bone 17 (4), 145S- 154S
Mathey & Savignac, Tetrahedron 34:649-654, 1978.
Mundy et ah, "Stimulation of bone formation in vitro and in rodents by statins," Science,
286:1946-1949, 1999. Roussis & Wiemer, J. Org. Chem., 54:627-631, 1989.
Claims
1. A substituted phosphonate compound of the formula (I):
zJ
Ar- ( I )
<
wherein Ar is:
and X° is H, OH or a straight or branched C\ to C6 alkoxy group,
X1, X2 and X3 are independently H, OH, a straight, branched, or cyclic - alkyl or alkoxy group;
0 1 2 3 or X , X or X , X together may form a C. - Cg optionally substituted alkyhdenoxy or alkylidenedioxy group; with the proviso that X° is H when X3 is H and X1 and X2 are independently straight or branched Ci-C6 alkyl groups; X4, X5, X6 are independently H, a straight or branched - C6 alkyl group; q is zero or 1;
X7 is H, a straight or branched Ci - Cg alkyl or alkoxy group, or an optionally substituted benzyl group;
Y is O or S;
Z1 and Z2 are independently OR1 or NR R , where R1, R , and R are independently H or a
1 2 straight or branched C.-C6 alkyl group, or Z , Z together may form a C2 - Cg alkylidenedioxy group; and
L is a saturated or unsaturated Ci-Cπ alkylene chain in which one or more of the methylene groups can be replaced by a sulfur atom, an oxygen atom, a carbonyl group wherein optionally one or more methylene groups can be substituted by one or more halogen atoms F, Cl or Br, C1-6 alkyl, an optionally substituted aryl or heteroaryl group; and pharmaceutically acceptable salts, solvates and hydrates thereof.
2. The compound of claim 1, wherein L is -A-C(O)-B- and A is a direct bond, -CH=C(R4)-, -CH2-C(R4)(R5)-, -C(R4)(R5)-, -O-C(R4)(R5)-, -S-C(R4)(R5)-, where R4,R5 are independently H, F, Cl, Br, Ci - C6 straight or branched alkyl, or an optionally substituted aryl or heteroaryl, and B is -C(R6)(R7)- where R6,R7 are independently H, F, Cl, Br, Ci - C6 straight or branched alkyl, or an optionally substituted aryl or heteroaryl, or can form a saturated ring of C3 - C carbon atoms.
3. The compound of claim 2, wherein A is a direct bond, -CH=C(R4)-, -CH2-C(R4)(R5)- and R4 and R5 are H, and R6 and R7 are independently H, F, CH3, C2H5 or R6 and R7 together form cyclic C5H8.
4. The compound of claim 2, wherein is A is a direct bond, -CH=CH-, or -CH2-CH2-.
5. The compound of claim 4, wherein B is -CH2,-, -CF2-, -CH(CH3)-, -CF(CH3)-, -C(CH3)2-, -C(CH3)(C2H5)-,-C(C2H5)2- or -CH(c C5H8)-.
6. The compound of claim 1 , wherein Y is O.
7. The compound of claim 6, wherein X4 is butyl and X5 is H or methyl and q is 1.
8. The compound of claim 7, wherein X4 is tert-butyl and X5 is H.
9. The compound of claim 8, wherein Z and Z are the same and are OR .
10. The compound of claim 9, wherein R1 is methyl, ethyl or isopropyl.
11. The compound of claim 1, wherein said substituted phosphonate compound of the formula (I) is selected from the group consisting of:
dimethyl 4-(3 -methoxy-5 -methyl-4-hydroxyphenyl)- 1 , 1 -dimethyl-2-oxo-3-buten- 1 -ylphosphonate; dimethyl 4-(3,5-dimethoxy-4-hydroxyρhenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3,4,5-trimethoxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate; dimethyl 4-(4,5-dimethoxy-3-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3,5-diethoxy-4-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-ρhosphonate; dimethyl 4-(4-hydroxy-3 -methoxy-5-n-propylphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -ylphosphonate; dimethyl 4-(5-tert-butyl-2-hydroxy-3 -methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl- phosphonate; dimethyl 4-(3-cyclopentyloxy-4-methoxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3 ,5 -di-cyclop entyl-4-hydroxyphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -ylphosphonate; diethyl 2-(3 ,4,5-trimethoxyphenyl)- 1 , 1 -dimethyl-2-oxo-ethylphosphonate; dimethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3 ,5-di-tert-butyl-2-hydroxyphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3 ,5-di-tert-butyl-2-hydroxyphenyl)- 1 , 1 -diethyl-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 4-(3,5 -di-tert-butyl-2-hydroxyphenyl)- 1, 1 -diethyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3 ,5-di-tert-butyl-2-hydroxyphenyl)- 1 , 1 -cyclop entyliden-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)-l,l-cyclopentyliden-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-hydroxyphenyl)- 1 -fluoro- 1 -methyl-2-oxo-3-buten- 1 -yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3 ,5-di-tert-butyl-2-methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 4-(3 ,5 -di-tert-butyl-2 -methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl phosphonate; diisopropyl 4-(3 ,5 -di-tert-butyl-2-methoxyphenyl)- 1 , 1 -dimethyl-2-oxo-3-buten- 1 -yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l-methyl-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l-methyl-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l-fluoro-l-methyl-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3 ,5-di-tert-butyl-2-methoxyphenyl)- 1 -fluoro- 1 -methyl-2-oxo-3-buten- 1 -yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-difluoro-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-difluoro-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)- 1 , 1 -diethyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-cyclopentyliden-2-oxo-3-buten-l-yl phosphonate; diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-methyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l,l-dimethyl-2-oxoethylphosphonate; dimethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-fluoro-l-methyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butyl-2-methoxyphenyl)-l-fluoro-l-methyl-2-oxoethylphosphonate; dimethyl 4-(3,5-di-tert-butylphenyl)-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butylphenyl)-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3 ,5 -di-tert-butylphenyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl phosphonate; diethyl 4-(3,5-di-tert-butyl-phenyl)-l,l-dimethyl-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butylphenyl)-l-ethyl-l-methyl-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3 ,5 -di-tert-butylphenyl)- 1 , 1 -diethyl-2-oxo-3 -buten- 1 -yl phosphonate; dimethyl 4-(3,5-di-tert-butylphenyl)-l,l-cyclopentyliden-2-oxo-3-buten-l-yl phosphonate; dimethyl 4-(3,5-di-tert-butylphenyl)-l,l-fluoro-2-oxo-3-buten-l-yl phosphonate; diethyl 4-(3,5-di-tert-butyl-phenyl)-l,l-fluoro-2-oxo-3-buten-l-yl phosphonate; dimethyl 2-(3,5-di-tert-butylphenyl)-l-methyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butyl-phenyl)-l-methyl-2-oxoethylphosphonate; dimethyl 2-(3,5-di-tert-butylphenyl)-l , 1 -dimethyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butyl-phenyl)-l,l-dimethyl-2-oxoethylphosphonate; dimethyl 2-(3,5-di-tert-butylphenyl)-l-fluoro-l-methyl-2-oxoethylphosphonate; diethyl 2-(3,5-di-tert-butylphenyl)-l-fluoro-l-methyl-2-oxethylphosphonate; dimethyl 2-(3,5-di-tert-butylphenyl)- 1 , 1 -difluoro-2-oxoethylphosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate; diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)- 1 -methyl-2-oxo-3-buten- 1 -ylphosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo-3- buten- 1 -yl-phosphonate; diethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo-3-buten-
1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l-ethyl-l-methyl-2-oxo-3-buten-
1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-diethyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-cyclopentylidene-2-oxo-3- buten- 1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3 -tert-butyl-4-methoxy-5 ,6,7,8-tetrahydronaphthyl-2-oxo-3-buten- 1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate; diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo-3-buten-l-yl- phosphonate; diisopropyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl-l,l-dimethyl-2-oxo-3-buten-l- yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxo-3-buten-l-yl- phosphonate; diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo-3- buten- 1 -yl-phosphonate; diethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetiahydronaphthyl)-l-fluoro-l-methyl-2-oxo-3-buten-
1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-ethyl-l-methyl-2-oxo-3- buten- 1 -yl-phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-diethyl-2-oxo-3-buten-l-yl- phosphonate; dimethyl 4-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l,l-cyclopentylidene-2-oxo-3- buten- 1 -yl-phosphonate; diethyl 2-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-methyl-2-oxoethyl phosphonate; diethyl 2-(3-tert-butyl-4-methoxy-5,6,7,8-tetrahydronaphthyl)-l-fluoro-l-methyl-2-oxo- ethylphosphonate; dimethyl 4-(3-tert-butyl-5,5-dimethyl-4-hydroxy-5,6,7,8-tetrahydro-l-naphthyl)-l,l-dimethyl-2- oxo-3-buten-l-yl-phosphonate; dimethyl 4-(3 -tert-butyl-4-hydroxy- 1 -naphthyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl-pho sphonate; dimethyl 4-(3-benzyl-4-hydroxy- 1 -naphthyl)- 1 , 1 -dimethyl-2-oxo-3 -buten- 1 -yl-phosphonate; dimethyl 4-(3 ,5 -di-tert-butyl-2-hydroxyphenyl)- 1 , 1 -dimethyl-2-oxo- 1 -butyl-phosphonate; dimethyl 4-(5 -tert-butyl-2-hydroxy-3 -methoxyphenyl)- 1 , 1 -dimethyl-2-oxo- 1 -butyl-phosphonate and dimethyl 4-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-l,l-dimethyl-2-oxo- 1 -butyl-phosphonate.
12. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
13. A method of treating or preventing a bone disease or pathology by stimulating bone formation, comprising administering to a subject in need of such treatment an amount effective to stimulate bone formation of a substituted phosphonate compound of claim 1.
14. The method of claim 13, wherein said bone disease or pathology is selected from the group consisting of osteoporosis, Paget's disease, bone fracture, hormone-induced bone pathologies, hypeφarathyroidism, peridontal disease, post-plastic surgery, post-prosthetic joint surgery and post-dental implantation.
15. The method of claim 13, wherein said bone disease or pathology comprises hypercalcemia secondary to malignancies or hypeφarathyroidism.
16. The method of claim 13, wherein said bone disease or pathology comprises a condition arising from hypercalcemia.
17. The method of claim 16, wherein said condition arising from hypercalcemia is selected from the group consisting of calcification of soft tissue, calcification of surgical implants and calcification of arteries.
18. The method of claim 17, wherein said soft tissue is selected from the group consisting of kidney, vessel walls and heart values.
19. The method of claim 18, wherein said calcification of arteries is due to late stage atherosclerosis.
20. The method of claim 13, wherein said subject is characterized by a condition selected from the group consisting of osteoporosis, Paget's disease, bone fracture or deficiency, drug and hormone-induced bone pathologies, hypeφarathyroidism, periodontal disease or defect, post- plastic surgery, post-prosthetic joint surgery and post-dental implantation.
21. The method of claim 20, wherein said drug- and hormone-induced pathology is selected from the group consisting of corticoids, retinoids and vitamin D3 -induced bone pathologies.
22. The method of claim 13, wherein said subject is characterized by a condition selected from metastasis of cancer cells in bones, tumoral osteolysis, and hypercalcemia, wherein said hypercalcemia is secondary to malignancies.
23. The method of claim 13, wherein said metastasis of cancer cells in bone is osteolytic or osteoplastic bone metastasis.
24. The method of claim 13, wherein said subject is characterized by a condition selected from periodontal disease or defect, post-plastic surgery, post-prosthetic joint surgery and post- dental implantation.
25. The method of claim 13, further comprising administration to said subject an effective amount of a bone resoφtion inhibitor.
26. The method of claim 25, wherein said bone resoφtion inhibitor is selected from the group consisiting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, S-12911, raloxifene, simvastatin, atorvastatin, cerivastatin, vitamin D and calcitonin.
27. The method of claim 26, wherein said subject is characterized by a condition selected from the group consisting of osteoporosis, Paget's disease, bone fracture or deficiency, drug and hormone-induced bone pathologies, hypeφarathyroidism, periodontal disease or defect, post- plastic surgery, post-prosthetic joint surgery and post-dental implantation.
28. The method of claim 27, wherein said drug- and hormone-induced pathology is selected from the group consisting of corticoids, retinoids and vitamin D3-induced bone pathologies.
29. The method of claim 28, wherein said subject is characterized by a condition selected from metastasis of cancer cells in bones, tumoral osteolysis and hypercalcemia, wherein said hypercalcemia is secondary to malignancies.
30. The method of claim 29, wherein said metastasis of cancer cells in bone is osteolytic or osteoplastic bone metastasis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41209102P | 2002-09-19 | 2002-09-19 | |
US412091P | 2002-09-19 | ||
PCT/US2003/029080 WO2004026315A1 (en) | 2002-09-19 | 2003-09-18 | Substituted ketophosphonate compounds having bone anabolic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1551418A1 true EP1551418A1 (en) | 2005-07-13 |
EP1551418A4 EP1551418A4 (en) | 2006-05-03 |
Family
ID=32030802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03752401A Withdrawn EP1551418A4 (en) | 2002-09-19 | 2003-09-18 | Substituted ketophosphonate compounds having bone anabolic activity |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1551418A4 (en) |
JP (1) | JP2006504697A (en) |
AU (2) | AU2003299029A1 (en) |
WO (2) | WO2004026245A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8466096B2 (en) | 2007-04-26 | 2013-06-18 | Afton Chemical Corporation | 1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions |
EP2324041A4 (en) | 2008-08-13 | 2012-06-13 | Targanta Therapeutics Corp | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
WO2010054966A2 (en) * | 2008-11-13 | 2010-05-20 | Basf Se | Benzylidene compounds comprising phosphono-groups |
EP2270021A1 (en) | 2009-06-18 | 2011-01-05 | Centre National de la Recherche Scientifique | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability |
EP2816049B8 (en) * | 2013-06-20 | 2018-07-11 | Ivoclar Vivadent AG | ß-ketophosphonic acids and all dental materials based thereon |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1372541A (en) * | 1971-07-14 | 1974-10-30 | Ici Ltd | Cyclopentane derivatives |
US3982016A (en) * | 1975-08-06 | 1976-09-21 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
EP0163270A2 (en) * | 1984-05-23 | 1985-12-04 | Green Cross Corporation | A lipoxygenase inhibitor |
WO1994019358A1 (en) * | 1993-02-19 | 1994-09-01 | Symphar S.A. | Substituted phosphonates, the processes for their preparation and pharmaceutical compositions containing them |
US5508273A (en) * | 1993-12-30 | 1996-04-16 | Ortho Pharmaceutical Corporation | Substituted phosphonic acids and derivatives useful in treating bone wasting diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0377894A (en) * | 1989-08-18 | 1991-04-03 | Toray Ind Inc | Methylene diphosphonic acid compound |
EP0544812B1 (en) * | 1990-08-21 | 1995-04-05 | The Upjohn Company | Bisphosphonic acid derivatives as anti-arthritic agents |
-
2003
- 2003-09-18 EP EP03752401A patent/EP1551418A4/en not_active Withdrawn
- 2003-09-18 WO PCT/US2003/029392 patent/WO2004026245A2/en not_active Application Discontinuation
- 2003-09-18 AU AU2003299029A patent/AU2003299029A1/en not_active Abandoned
- 2003-09-18 AU AU2003270693A patent/AU2003270693A1/en not_active Abandoned
- 2003-09-18 JP JP2004537860A patent/JP2006504697A/en active Pending
- 2003-09-18 WO PCT/US2003/029080 patent/WO2004026315A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1372541A (en) * | 1971-07-14 | 1974-10-30 | Ici Ltd | Cyclopentane derivatives |
US3982016A (en) * | 1975-08-06 | 1976-09-21 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
EP0163270A2 (en) * | 1984-05-23 | 1985-12-04 | Green Cross Corporation | A lipoxygenase inhibitor |
WO1994019358A1 (en) * | 1993-02-19 | 1994-09-01 | Symphar S.A. | Substituted phosphonates, the processes for their preparation and pharmaceutical compositions containing them |
US5508273A (en) * | 1993-12-30 | 1996-04-16 | Ortho Pharmaceutical Corporation | Substituted phosphonic acids and derivatives useful in treating bone wasting diseases |
Non-Patent Citations (4)
Title |
---|
GRECO M N ET AL: "Nonpeptide Inhibitors of Cathepsin G: Optimization of a Novel.beta.-Ketophosphonic Acid Lead by Structure-Based Drug Design" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 124, no. 15, 17 April 2002 (2002-04-17), pages 3810-3811, XP002231848 ISSN: 0002-7863 * |
SAKODA R. ET AL.: "Novel synthesis of alpha-acetylstyrylphosphonates" SYNTHESIS., no. 7, 1993, pages 705-713, XP002371174 DE GEORG THIEME VERLAG, STUTTGART. * |
SCHWENDER C F ET AL: "1-Naphthylmethylphosphonic acid derivatives as osteoclastic acid phosphatase inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 16, 17 August 1995 (1995-08-17), pages 1801-1806, XP004135368 ISSN: 0960-894X * |
See also references of WO2004026315A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003299029A1 (en) | 2004-04-08 |
WO2004026315A1 (en) | 2004-04-01 |
JP2006504697A (en) | 2006-02-09 |
WO2004026245A8 (en) | 2004-07-22 |
WO2004026245A2 (en) | 2004-04-01 |
EP1551418A4 (en) | 2006-05-03 |
AU2003270693A1 (en) | 2004-04-08 |
AU2003299029A8 (en) | 2004-04-08 |
WO2004026245A3 (en) | 2004-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3526575B2 (en) | Phosphonic acid derivatives | |
JP5823862B2 (en) | Imidazo [1,2-α] pyridinyl bisphosphonate | |
JP5244917B2 (en) | C2-C5-alkyl-imidazole-bisphosphonates | |
US5312814A (en) | α-phosphonocarboxylate squalene synthetase inhibitors | |
JPH0222285A (en) | Phenol substituted diem-diphosphonate derivative and preparation thereof and pharmaceutical composition containing the same | |
JP3224817B2 (en) | New methylenebisphosphonic acid derivatives | |
US4732998A (en) | Bisphosphonic acids and esters | |
EP0248854B1 (en) | Novel bisphosphonic derivatives, a method for their production and a pharmaceutical composition | |
JP2701952B2 (en) | N-Heterocyclic propylidene-1,1-bisphosphonic acid, its preparation and pharmaceutical composition | |
RU2079504C1 (en) | New derivatives of bis-phosphonic acid and method of their synthesis | |
RU2124019C1 (en) | Thiosubstituted pyridinylbisphosphonic acids or their pharmaceutically acceptable salts or esters, pharmaceutical composition based on thereof and method of treatment | |
WO2004026315A1 (en) | Substituted ketophosphonate compounds having bone anabolic activity | |
RU2074860C1 (en) | Derivatives of methylene-bis-phosphonic acid | |
RU2136691C1 (en) | Sulfur-containing phosphonic acids or their pharmaceutically acceptable salts or esters and pharmaceutical composition based on said | |
JP2004505908A (en) | Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases | |
AU664761B2 (en) | Thio-substituted cyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism | |
WO2004026243A2 (en) | Therapeutic uses of linear ketophosphonates | |
Mansfield | The synthesis of novel agents which inhibit tumour-stimulated bone resorption | |
HU184813B (en) | Process for preparing diphosphonate derivatives | |
CZ20001245A3 (en) | Anhydride derivatives of methylenebisphosphonic acid, process of their preparation and pharmaceutical preparation containing thereof | |
EP1482953A1 (en) | Alpha-substituted heteroarylalkyl phosphonate derivattives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050419 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060322 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060623 |